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dispersed phase is forced through an orifice in a planar membrane into a simple shear flow set up by a
second continuous phase flowing parallel to the membrane surface, thereby generating an emulsion.
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ABSTRACT

THE PHYSICS OF MEMBRANE EMULSIFICATION AND APPLICATIONS FOR
CONTROLLED DRUG DELIVERY

Robert F. Meyer

John C. Crocker

In many applications employing particles, the distribution of particle sizes has
significant influence over the properties of the resultant material, and this holds
especially true for many pharmaceutical products. In the case of depot formulations
made of drug-loaded polymer microspheres, particle size significantly impacts the rate
and duration of drug release.

Thus, if particle size can be controlled, formulation

characteristics can be engineered to better meet the needs of the specific situation. Crossflow membrane emulsification (XME) is a method for manufacturing uniformly sized
emulsion droplets which can be used for many applications, including production of
drug-loaded polymer microspheres. In XME, a dispersed phase is forced through an
orifice in a planar membrane into a simple shear flow set up by a second continuous
phase flowing parallel to the membrane surface, thereby generating an emulsion. Though
XME has become a popular technique for researchers generating monodisperse
emulsions, there has been insufficient characterization of the physics of the XME
vi

process. This is true for both simple binary fluid systems, as well as the more complex
fluid systems used for the generation of drug-loaded microspheres. In this work, we
describe a unique XME system that allows for visualization of the process, providing
access to details likely unseen by previous researchers. First employing our system for
the study of pure fluids, we successfully show that a simple force balance can be used to
model the size of emulsion droplets as a function of process conditions. We also show
that the range of applicability of our model corresponds to the region of simple fluid
dripping, and that the XME process undergoes a dripping-jetting transition much like the
common household faucet.

Extending the methods to a more complex case when

dissolved polymers, drugs and surfactants are present, we find generally that our earlier
results hold true, but only if dynamic interfacial tension is taken into account. Ultimately
we show that drug-loaded polymer microspheres of uniform size can be reliably and
predictably manufactured across a range of process conditions, and thus we conclude that
XME has the potential to produce advanced controlled release formulations.
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Chapter 1: Introduction
1.1 Research Motivation
For many chronic conditions, the success a drug has in managing a disease is
directly related to how well the drug concentration is maintained within the therapeutic
window that maximizes efficacy and minimizes side effects. Traditional drug therapy
usually consists of an oral dosage form that is administered once daily. Although this has
been standard for many years, this route of administration can lead to variability due to
many factors, including poor patient compliance to the recommended dosing schedule,
and interaction of the drug or formulation with food and drink.

Furthermore, this

administration route suffers from the drawbacks that many drugs are degraded or poorly
absorbed in the gut, and first-pass metabolism can significantly reduce the amount of
drug that reaches circulation. Oral administration also results in a drug being dosed to the
entire body, rather than being delivered to only the desired location. Because these
mechanisms increase the total amount of drug that must be administered to reach the
target concentration in the blood, and because different patients absorb and metabolize
drugs differently, significant variability can be seen between patients taking oral
medication.

Ultimately, deviation of drug concentration outside of the therapeutic

window can lead to a higher incidence of side effects or relapse, and in some instances, it
can lead to patient hospitalization.
Parenteral drug formulations circumvent many problems associated with oral
administration, and thus have inherent advantages over traditional therapy. Although
they are more expensive to manufacture and generally must be administered by a medical
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professional, parenterals have benefits such as lower dose, local delivery, and reduced
variability between patients.

Long acting release (LAR) parenteral formulations in

particular have been shown to improve patient compliance, reduce drug variability and
side effects, improve clinical outcomes, and decrease hospitalizations and the cost of
care1-4. For these reasons, advancing the science geared towards development of such
treatment forms is a valuable research goal.

1.2 Background
There are many approaches for developing LAR parenteral formulations, and
embedding drug in a matrix of polymer is certainly one of the more popular strategies. In
a classical method used to manufacture drug-loaded microparticles, an organic solvent is
mixed with drug and a biodegradable polymer to form the dispersed phase, while water
and surfactant form the continuous phase.

The dispersed phase is emulsified in the

continuous phase, and then the organic solvent is extracted and evaporated, resulting in
solid drug-loaded polymer microspheres. After washing and drying, the microspheres
form a drug product suitable for parenteral administration. Microspheres such as these
have been developed as several drug products used to provide release periods ranging
from 1 week to 6 months.
There have been at least 10 commercial products of this type developed for the
U.S. market over the last 20 years5. Although these LAR products all improve upon
formulations that are administered daily, no formulation has achieved the gold standard
of a constant drug release rate over an extended period.

Instead, current LAR

formulations reduce the daily rise and fall of drug levels in the body, and instead provide
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drug levels that rise and fall a few times a month. As an example of this, we examine
clinical data from a study that compared an oral and LAR formulation of naltrexone, an
opioid receptor antagonist used for treatment of alcohol dependence.

Figure 1.1 – Pharmacokinetic profiles of immediate release (IR)
and long acting release (LAR) formulations of naltrexone.

Figure 1.1 displays our graphical representation of pharmacokinetic data extracted
from a clinical study comparing an immediate release (IR) 50 mg once-daily oral dose of
naltrexone to a LAR 380 mg once-monthly intramuscular microsphere injection3. For
drugs such as naltrexone, the optimal formulation would rapidly raise the level of drug in
the patient's blood stream to the desired concentration, and would then maintain that
same concentration, releasing additional drug at the same rate that the body eliminates it
from circulation. The LAR formulation clearly eliminates the daily rise and fall of drug
levels in the blood when compared to the IR formulation, but it is far from the ideal
formulation, which would maintain concentrations at near constant levels. Instead, it
exhibits a tri-phasic release profile, with peaks on days 0, 3 and ~15. Although this is not
of significance for this drug, in many cases the spike seen in the LAR formulation can
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cause increased side effects or disease flare-up6. Thus, microsphere formulations that can
better control rate and extent of drug release will in many cases result in improved patient
care and better clinical outcomes.
Because drug is released from microspheres by both diffusion through and
degradation of the polymer matrix, stringent control over particle size is a convenient
method for manipulating release rate. This general concept has been demonstrated by
several researchers who used high shear emulsification to produce microspheres with
wide particle size distributions, then sieved the product into several size fractions, each
with its own unique release profile7-9. The transport of drug through the microspheres
was modeled as a function of particle diameter, while also taking polymer degradation
rate into account. Finally, Berchane et al.9 showed that by mixing microspheres with
different sizes and polymer molecular weights, they could achieve a pre-specified release
profile.

1.3 Research Aims
Because

most

emulsification

techniques

used

for

generating

polymer

microspheres result in polydisperse particle size distributions, a technique that allows for
accurate and precise particle size control would be a significant improvement in the state
of the art. In this thesis, we aim to develop a robust and scalable manufacturing method
for continuously producing sterile monodisperse polymer microspheres.

We aim to

develop a theoretical understanding of how process conditions affect particle size, by first
studying the emulsification of pure, simple fluids.

Then we aim to expand this

understanding to non-ideal fluid systems used for generating drug-loaded polymer
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microspheres.

We aim to use this understanding to demonstrate our manufacturing

method's utility for producing large quantities of drug loaded polymer microspheres.
Finally, we aim to lay the groundwork for developing an ideal microsphere formulation
exhibiting the desired rate and extent of release, including development of a system for
testing this drug release in vitro.

1.4 Thesis Outline
This thesis is organized as follows. In Chapter 2, we first review polymer-based
controlled release dosage forms in general.

Then we look at the methodology for

generating polymer microsphere formulations using emulsification followed by solvent
extraction and evaporation. With that as a backdrop, we review the state of the art for
producing monodisperse emulsions, including the methods of manufacture and
mathematical descriptions of the processes. We focus this review specifically on the
technique known as cross-flow membrane emulsification. Then we examine research
where monodisperse emulsions were produced from systems containing polymers and
surfactants. Finally, we review in greater detail instances where control over particle size
was used as a method to manipulate drug release from polymer microsphere
formulations.
In Chapter 3, we describe the materials and methods used in this research.
Specifically, we describe the apparatus that we developed for manufacturing
monodisperse emulsions. We also describe the equipment and methods for examining
the emulsion production process. We explain our techniques for measuring physical
properties relevant to emulsions, and some results from those measurements. And we
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give details on efforts to characterize our emulsification system, through both basic
mathematical as well as more advanced numerical modeling.

Finally, we provide

additional details on the materials used to generate polymer microparticles, the model
drug we load into the particles, and our method for measuring drug release from the
particles.
In Chapter 4 we describe the production of monodisperse emulsions of simple
fluids using cross-flow membrane emulsification. This work, titled "Universal Dripping
and Jetting in a Transverse Shear Flow", has been previously published in Physical
Review Letters in May 2009.10

A model for predicting the size of droplets as a function

of system geometry, process flow rates and physical properties is presented. We also
describe where the system transitions from dripping to jetting, and draw comparisons to
the well-studied case of the dripping faucet.
Chapter 5 describes our efforts to expand cross-flow membrane emulsification
from simple, pure fluid systems to more complicated systems containing dissolved
polymers and surfactants. This work, titled, "Producing Monodisperse Drug-Loaded
Polymer Microspheres via Cross-Flow Membrane Emulsification: The Effects of
Polymers and Surfactants", was previously published in Langmuir in September 2010.11
We show that emulsions generated from both simple and complex fluids can be produced
across a range of sizes and rates, and the models that describe the size of the resultant
droplets work reasonably well for both systems. We show that dynamic interfacial
tension affects the size of droplets, especially at low production rates, but that fluid
viscosity and elasticity behave ideally under the conditions studied. Finally, we show
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that cross-flow membrane emulsification can be used to generate highly uniform solid
drug-loaded polymer microspheres.
Chapter 6 contains a description of future work that could be performed to
translate the demonstrated manufacturing methods into a commercializable formulation
of a model drug, haloperidol. Literature is reviewed that describes LAR formulations of
haloperidol, including a manuscript that we contributed to, "A rapid method for creating
drug implants: Translating laboratory-based methods into a scalable manufacturing
process", published in the Journal of Biomedical Materials Research Part B: Applied
Biomaterials in May 2010.12 Specifically, we lay out the calculations for what a 30 day
LAR formulation of haloperidol would look like, and describe the emulsification and in
vitro release experiments to be performed in order to achieve the goal of generating an
ideal drug release profile.
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Chapter 2: Literature Review
2.1 Marketed long acting release medications and their
formulations
Development of long acting release (LAR) formulations of drug encapsulated in a
matrix of polymer is a commercially viable formulation strategy, and several products of
this type are approved for marketing in the United States. Gliadel Wafers® (polifeprosan
20 with carmustine implant) are used to treat individuals with high-grade malignant
blastoma.

The biodegradable discs are implanted directly into the brain during

craniotomy, and have been shown to extend patient lives by delivering an extended dose
of drug higher than what is tolerable when the drug is delivered systemically1. Zoladex®
(goserelin acetate implant) is used for treating patients with advanced cancers of the
prostate. The 1 mm diameter biodegradable rod is implanted subcutaneously and releases
a synthetic hormone for a 1 or 3 month period. Lupron Depot®, Vivitrol®, and Risperdal
Consta® are all biodegradable microsphere based formulations.

Lupron Depot®

(leuprolide acetate for depot suspension), available in 1 to 4 month formulations, is
indicated for men with prostate cancer, similar to Zoladex®, and is also indicated for
women with endometriosis or fibroids, and children with central precocious puberty.
Vivitrol® (naltrexone for extended-release injectable suspension) is indicated for
treatment of alcohol dependence, and is delivered as an intramuscular injection that is
dosed every 4 weeks. Risperdal Consta® (risperidone) long acting injection, indicated for
the treatment of bipolar I disorder as well as schizophrenia, is administered every 2
weeks as a deep intramuscular injection2. Finally, NuvaRing® (etonogestrel /ethinyl
estradiol vaginal ring) is a non-biodegradable contraceptive ring which releases two
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hormones over a three week period, and is a popular alternative to daily contraceptive
pills. All of these products have been shown clinically to improve patient outcomes
relative to short acting daily doses of the same or similar medicines.
The LAR formulations currently available on the U.S. market come in a variety of
shapes and sizes, and those specific products just described are formed into the shapes of
rings, discs, rods and microspheres. The polymers used to formulate LAR products are
just as varied. The non-biodegradable copolymer as ethylene-vinyl acetate (EVA) has
been used successfully, and there are several biodegradable polymers in use either in
research or on the market, such as polycaprolactone (PCL), poly(lactic acid) (PLA),
poly(glycolic acid) (PGA), and copolymers such as

poly[bis(p-carboxyphenoxy)

propane-co-sebacic acid] (polifeprosan) and poly(DL-lactide-co-glycolide) (PLG)3. The
biodegradable polymers are all polyesters, and degrade through hydrolytic cleavage of
the ester bond, thus releasing the payload of drug.
Of the many polymers and geometries that could be studied for generating LAR
formulations, we choose to focus on PLG based microspheres. The PLG copolymer
certainly has been studied the most, and has enjoyed commercial success in a number of
products, including Zoladex® rods, and Lupron Depot®, Vivitrol®, and Risperdal Consta®
microspheres. A wide variety of types of PLG are available off the shelf. Specifically,
the following traits can be altered so as to tune polymer hydrophilicity, crystallinity,
degradation rate, and ultimately drug release rate. These traits are adjustable by varying
the lactide to glycolide ratio (100:0 to 50:50), the polymer molecular weight (10 kDa to
140 kDa), and the polymer end group (acid or ester terminus). Microspheres are studied
frequently as well, and methods for their manufacture are numerous. The particles can be
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delivered via injection with a small needle, and including those listed above, at least 10
products have been commercialized for the U.S. market3.

2.2 Methods of manufacture for long acting release
formulations
The most basic method for encapsulating drugs within PLG microspheres is
known in the literature as the oil-in-water (o/w) emulsion solvent extraction method3.
This method is depicted graphically in Figure 2.1. In the method, the continuous phase
(CP) is prepared through mixing water with a surfactant, typically poly(vinyl alcohol).
The dispersed phase is prepared by mixing the drug and polymer together with an organic
solvent, typically dichloromethane. The dispersed phase is then emulsified within the
continuous phase using any number of methods. The organic solvent is chosen such that
it is sparingly soluble in water, and can thus be extracted slowly over time. As the
solvent is extracted, the emulsion droplets shrink and solidify, ultimately yielding solid
drug-loaded polymer microspheres.

As a final step, the microspheres are washed to

remove any residual surfactant, and either filtered and air dried, or lyophilized while
contained within a suspending medium.
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Figure 2.1 – Oil-in-water emulsion / solvent extraction method for
producing drug-loaded polymer microspheres.

In order to generate drug-loaded polymer microspheres using the method
described above, we need only pick the formulation and the emulsification method. The
other steps can follow the common recipes available in the literature. Focusing first on
the emulsification method, we seek a technique that is robust, scalable, continuous, and
can generate sterile monodisperse particles over a wide size range.

2.3 Methods of manufacture for uniformly sized emulsions
There are many ways to make particles, and the general technique is to start with
something big and make it small through application of force.

When generating

dispersions, high-shear emulsification and spraying processes are two common high12

throughput techniques that result in wide particle size distributions. The key to making
uniform particles is to control the balance of forces between what holds particles
together, and what tears them apart. For liquids, interfacial tension is the key force
holding the liquid together, while a variety of forces can be used to tear a liquid apart.
Here we will briefly review some of the major methodologies.
Dripping of a liquid by gravity from a household faucet is the most common
example of how uniform droplets can be generated through the application of a force, and
perhaps because of its common occurrence, the system has been studied in great detail.
Harkins and Brown wrote a classic paper in 1919 that described the size of droplets
produced from a dripping needle tip in relation to the diameter of the needle, the fluid
density and the strength of the interfacial tension force4.

The analysis is not as

straightforward as one might initially assume, because the size of the drop that falls is
always smaller than a simple force balance would predict. They then turned the analysis
around, and proposed measuring the weight of a falling drop as a means of determining
the interfacial tension of a fluid. This method remains popular today, but a sound
theoretical analysis of the system was not developed until recently. In 1993, Eggers
wrote a paper that described the nature of the hydrodynamic singularity which occurs
when a droplet detaches from a needle tip.5 Then in 1994, Eggers and Dupont wrote a
paper describing a one-dimensional "slender jet" approximation to the Navier-Stokes
equation that could be applied to the case of the dripping faucet6. This development was
important, because it enabled the use of computers to numerically simulate the dripping
faucet geometry in a time-efficient manner. Finally, in 2005 Yildirim et al. published a
paper called "Analysis of the Drop Weight Method", which utilized the equations of
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Eggers and Dupont to perform a vast number of numerical simulations7. They were able
to numerically simulate the original results of Harkins and Brown, and also rephrase as a
dimensionless correlation the dimensionless drop size as a function of the ratio of
gravitational and interfacial tension forces, ultimately showing that by understanding the
balance of forces, we can predict the size of particles being made.
Gravity is a good force to use for generating droplets because it is widely
available, but other forces such as electrostatic repulsion, mechanical motion, and fluid
drag have the benefit of being adjustable, and thus the applied force can be tuned to break
off a droplet of exactly the desired size. Electro-hydrodynamic atomization (EHDA) is
an interesting application of this idea. In EHDA, a liquid is pumped through a needle tip,
and an electric potential is applied between the needle and a counter-electrode. When the
electrostatic force exceeds the surface tension force, a thin column of liquid jets from the
needle tip, and the column subsequently breaks up into monodisperse drops8-9. The
technique suffers from the drawback of painstakingly low flow rates (on the order of 100
µL/hr), a problem that can be addressed through multiplexing.10 Using this method,
droplets in the size range of hundreds of nanometers up to around 10 µm have been made
for purposes that include drug delivery11-13.
A particularly exciting example of monodisperse droplet generation using
mechanical vibration was described by Berkland et al.14 In their method, a column of
liquid flows through a needle or other orifice so that the liquid jets. Using a piezoelectric
transducer, a mechanical vibration is applied to the needle that precisely matches the
most unstable wavelength predicted by Rayleigh's classic linear stability analysis15. This
mechanical forcing causes the liquid column to break up into a uniform stream of
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droplets, and droplet sizes in the range of 25 to 500 µm have been generated. The
method has been used to generate drug-loaded PLG microspheres,16-17 and by mixing
different monodisperse lots, they produced formulations that exhibit a constant release
rate. Unfortunately, the method has been patented, and little work has been performed
outside of the originating laboratory. Still, their pioneering work was early proof of the
concept of engineered release profiles, and we seek to improve upon the efficiency and
scalability of their technique.
Another example of monodisperse droplet generation through application of a
controlled force was presented by Umbanhowar, Prasad and Weitz.18 In that work,
monodisperse droplets were produced by immersing a bent needle into a fluid vessel
undergoing solid body rotation, thus generating a co-flowing liquid stream at the needle
tip. The size of the droplets is determined by the balance of drag and interfacial forces,
and a model to predict droplet diameter based on this force balance was presented.
Droplet diameters between 2 and 200 µm were generated. Subsequent studies in the
same laboratory resulted in a related technique, where a circular needle was centered
within an outer square tube, and monodisperse emulsions were generated.19 An even
more unique geometry was presented by this laboratory, where a third collection tube was
centered downstream from the circular injection needle and the square outer tube. Using
this geometry, they were able to generate monodisperse double emulsions, including
core-shell microcapsules with tunable wall thickness.20

This technique, commonly

called flow focusing, has enjoyed significant popularity and has been the subject of
numerous investigations.
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2.4 Review of cross-flow membrane emulsification
Instead of making particles by applying drag from a co-flowing liquid stream, a
cross-flowing liquid stream can be used. When instead of a capillary, a microporous
membrane is used, the technique is called cross-flow membrane emulsification (XME).
When comparing all of the techniques for generating monodisperse particles, we find that
XME meets our criteria, in that it is robust, scalable, continuous, and can generate sterile
monodisperse particles over a wide size range. A diagram depicting the XME process is
displayed in Figure 2.2.

Figure 2.2 – Diagram of cross-flow membrane emulsification
(XME).

In XME, the DP is forced by pressure through a membrane containing one or
multiple small pores. Meanwhile, the CP flows tangentially over the membrane surface.
Because the phases are immiscible, when the DP contacts the CP, a droplet grows at the
membrane surface. As the droplet grows, the drag from the CP increases, until such point
that the drag force exceeds the interfacial tension force. The droplet then detaches from
the membrane surface, and the process repeats. When the flow rates from the two phases
are constant, the process reaches a steady state, and the droplet grows to a repeatable size
over and over again, yielding a monodisperse emulsion. And by adjusting either the drag
force or the interfacial tension force, different sizes of droplets can be produced.

16

Experiments described in later chapters show that droplet size is either independent or
only a weak function of DP flow rate, a result that improves process robustness. If
components are fabricated from materials such as stainless steel and fluoroelastomer,
then they can be sterilized through autoclaving, and thus are suitable for sterile
processing. Finally, the process is scalable, because membranes with multiple pores can
be used such that the desired mass throughput is obtained. Thus, the method meets the
requirements we set for selection.
Cross-flow membrane emulsification belongs to a more general class of
membrane emulsification methods, and these methods are reviewed at the start of
Chapters 4 and 5. Looking just at XME, researchers have used numerous techniques to
generate the cross-flow shown in Figure 2.2, and a variety of methods have been used to
manufacture the microporous membrane. Kosvintsev et al. adapted a cone and plate
rheometer, well known to produce constant shear across the surface of the plate21. In that
study, they used commercially available silicon nitride membranes etched onto a silicon
substrate, which exhibit a beautiful uniform array of straight-through microchannels.
Surprisingly, their study resulted in fairly polydisperse particles.

Furthermore, they

concluded that particles produced using the cone and plate geometry were no more
uniform than those produced using a standard paddle stirrer. The same research group
later went on to produce drug-loaded microparticles using this method, but drug release
profiles were not significantly more uniform than those based on conventional
emulsification techniques22-23.
Kobayashi et al. were one of the first research groups to use photolithography to
generate silicon microporous membranes, and then use those membrane to generate
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emulsions using XME.24-25 They were unique in that they generated both circular as well
as oblong pores, and they concluded that oblong pores result in a more uniform size
distribution, though this result has not been widely repeated by others, and circular pores
are still the most common.
Although not purely XME due to the presence of centrifugal forces, an interesting
example of membrane emulsification using a rotating laser drilled stainless steel
membrane was demonstrated by Vladisavljevic and Williams.26 Their study operated in
batch mode, with the membrane tube spinning within an outer stationary fluid vessel,
though a continuous set up was also described. They showed that the low shear rates
throughout their setup made possible the generation of large, shear labile droplets.
Ultimately, their method produced droplets from 80 to 260 µm with uniformity of 5 to
20%.
Perhaps the most popular XME technique involves the use of Shirasu Porous
Glass (SPG) as the membrane. In this method, a DP is pumped through a (typically)
cylindrical annulus made of microporous glass and into a cross-flowing CP.27 This
method has also been successfully used for generating drug-loaded polymer
microparticles, and one group of researchers generated PLA microparticles using both the
XME SPG technique, as well as via conventional high shear emulsification.28-29 They
found that both particle size uniformity as well as drug encapsulation efficiency were
better for the XME technique. Unfortunately, SPG membranes are fragile, and are not
amenable to sterile processing, and thus are unsuitable for commercial applications.
Looking now at the physics of XME, because of the well defined geometry and
fluid properties, the basic system is amenable to both classical force balance descriptions,
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as well as numerical simulations.

Abrahamse et al. published the earliest known

computational fluid dynamics (CFD) simulation of the XME process, and we later
followed their approach for our own modeling.30 CFD is particularly useful for gaining
insight into the details of the XME process, and Abrahamse et al. published results
showing how the pressure drop over and velocity within the pore is time-dependent, and
also how the CP penetrates into the pore near the point of droplet snap off.
A number of researchers have tried to apply force and/or torque balances to
predict droplet size during XME. Peng and Williams were one of the first to apply theory
to their experimental results.31 They used a single 46 µm glass capillary embedded in
epoxy and mounted within a 10 mm x 40 mm stainless steel flow channel. Their
theoretical method took into account drag, interfacial, buoyant and inertial forces, and
though their graphical representation displayed good agreement between experiment and
theory, they presented only 5 experimental data points of droplet size vs. CP flow
velocity, with too little supporting information to draw an independent conclusion.
An excellent application of the force balance approach to modeling of droplet size
as a function of process conditions was performed by Husny and Cooper-White.32 Their
work focused on modeling of droplet formation in T-shaped microchannels, which are a
microfluidic analog to XME. Unlike traditional XME, in the T-shaped microchannel
geometry the "pore" spans the entire width of the CP channel, and thus the resultant
droplets also span nearly the width of the channel. Despite these complications, they
presented a sophisticated force balance, as well as copious data to support their
predictions. Furthermore, the DP in their fluid system contained a dissolved polymer,
poly(ethylene oxide), and they showed the effect of changes of polymer molecular weight
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and viscosity ratio, and how under certain conditions satellite droplets resulting from the
long fluid neck were produced along with the primary droplets.

2.5 Application of controlled emulsification for engineered drug
release
Numerous examples have been presented demonstrating how drug-loaded
microparticles can be generated from controlled emulsification techniques. We also refer
the reader to three recent review papers that discuss emulsification techniques including
those described above, as well as other information of relevance to those seeking to
produce polymer based drug-loaded microparticles.3, 33-34
Taking the design to the next level, and using monodisperse particles to engineer
formulations with the desired release rate is a problem that has been studied by far fewer
researchers. Two research groups have made substantial contributions, and both groups
solved the time-dependent diffusion equation with molecular weight dependent
diffusivity.35-37

∂c 1 ∂ ⎛
2 ∂c ⎞
= 2
⎜ D( M w (t ))r
⎟
∂t r ∂r ⎝
∂r ⎠

(2.1)

In the equation, c is the drug concentration, r is the radial position within the
microsphere, D is the drug diffusivity within the polymer matrix, Mw is polymer
molecular weight, and t is time. The relationship of Mw with time is typically reported to
be log linear, ln(Mw) = mt + b, and that again is the case here. The Pack Laboratory at the
University of Illinois went further, and measured the initial distribution of drug in the
microspheres using confocal fluorescence microscopy, and then used those data as the
model initial condition. Both research groups were able validate their models for the
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release of drug from monodisperse microspheres, and they also used polymer molecular
weight and microsphere size as design parameters for engineering the desired release
profile.
This concludes what is only a brief review of the hundreds of papers that we have
looked to for ideas and inspiration during the generation of this research. Thus as we
begin the chapters devoted to our own research, we end with a quotation often wrongly
attributed to Isaac Newton, but still very appropriate for any researcher: "Bernard of
Chartres used to compare us to dwarfs perched on the shoulders of giants. He pointed out
that we see more and farther than our predecessors, not because we have keener vision or
greater height, but because we are lifted up and borne aloft on their gigantic stature."38
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Chapter 3: Materials, Methods, and Preliminary Results
3.1 Cross-Flow Membrane Emulsification
Membrane emulsification describes a wide variety of techniques whereby a
dispersed phase (DP) is forced through an orifice in a membrane into an immiscible
continuous phase (CP), thereby generating an emulsion. A subset of this wide field is
cross-flow membrane emulsification (XME), where nascent drops are formed at the
membrane pore while subjected to a transverse shear flow. This process is represented
below in Figure 3.1. The drag force exerted by the CP increases as the drop grows larger,
until such point that the interfacial tension force can no longer hold onto the drop, after
which the drop detaches and the process begins anew. It is this balance of drag and
interfacial tension forces which allows for precise control over the size of the droplets
which are produced via XME.

Figure 3.1 – Schematic of the XME process and important
parameters.

This chapter is organized as follows. First we describe the method and apparatus
for generating emulsions via XME, followed by the visual and data recording systems.
Next we describe the preparation of simple and complex fluid pairs, and the measurement
of relevant physical and particle properties. We describe the mathematics particular to
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the fluid flow in our XME apparatus, and numerical simulations of those flows. Next,
downstream processing techniques for generating solid microspheres from emulsions
made via XME are described. Finally, we describe a model drug and an inline system for
testing drug release from solid microspheres. Where appropriate, we have included
preliminary results from the described techniques so as to validate the results and
illustrate their utility.

3.1.1 Membrane Emulsifier
A system for producing emulsions via cross-flow membrane emulsification is
shown in Figure 3.2 and Figure 3.3. Both CP and DP are pumped into their respective
inlets from the bottom of the membrane holder. After changing direction, the CP flows
along the membrane surface down a long rectangular channel 6.4 mm wide by 3.2 mm
high. In some experiments, a solid insert is placed in the channel to decrease the height
to 1.0 mm. In the center of the channel, DP passes through the membrane and into the
cross-flowing CP, generating a droplet. The emulsion then travels down the remainder of
the channel, and exits the membrane holder at the bottom, and finally proceeds to the
collection vessel.

Figure 3.2 – Solid representation of membrane emulsifier flow
channels, membrane and optical path.
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The membrane holder is machined from two highly polished 4 in. square blocks
of aluminum alloy 6061, between which the membrane is sandwiched. Two concentric
rings contain double-seal Viton o-rings, thus sequestering the DP from the CP, and the
CP from the ambient environment. The membrane holder top and bottom are connected
via four ¼"-20 stainless steel screws. The 2 in. diameter membrane rests on the inner oring during assembly, and is machined such that the o-ring is compressed appropriately
and there is no lip between the membrane and the membrane holder. The two 0.063 in.
radius indentations in the membrane holder top are machined to hold two 1/8 in. right
angle prisms mounted flush with the fluid channel wall, and a solvent proof optical epoxy
holds the prisms in place. A 1 in. diameter sapphire window rests on top of the channel
and prisms, and this assembly allows the emulsification process to be viewed from both
the top and the side.

Figure 3.3 – Bottom view of membrane holder top (left), and top
view of membrane holder bottom (right).

Disk-shaped membranes are constructed of stainless steel and cut to 50 mm in
diameter from 0.30 mm thick sheet stock. For each membrane, a single pore is cut into
the center of the membrane using one of three methods: laser drilling (Oxford Lasers,
Shirley, MA), mechanical drilling (Roland Research Devices, Trenton, NJ), or electrical
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discharge machining (EDM) (Makino / Hummingbird Precision Machine Co., Lacey,
WA). The pore dimensions for the various membranes are shown in Table 3.1, as
measured via image analysis by fitting an ellipse to the pore perimeter.

Electron

micrographs showing the different membrane pores are provided in Figure 3.4 and Figure
3.5.
Table 3.1 – Summary of pore dimensions of membranes used for XME.

No.
1
1
2
3
3
4
5
6
7
8

Side
Front
Back
Back
Front
Back
Front
Front
Front
Front
Front

Method of
Manufacture
Laser drilled
Laser drilled
Laser drilled
Mech. drilled
Mech. drilled
EDM
EDM
EDM
EDM
EDM

Major
Minor
Average
Dia. (µm) Dia. (µm) Dia. (µm)
17
17
17
12
11
11
20
20
20
94
93
94
174
171
173
24
24
24
43
43
43
64
64
64
79
79
79
101
100
101
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Area Perimeter
(µm2)
(µm)
226
53
101
36
308
62
6904
295
23425
543
451
75
1464
136
3213
201
4868
247
7959
316

(a) Membrane 1 front side

(b) Membrane 1 back side

(c) Membrane 3 front side

(d) Membrane 3 back side

Figure 3.4 – SEM images of laser and mechanically drilled
membranes.
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(a) Membrane 4 front side

(b) Membrane 5 front side

(c) Membrane 6 front side

(d) Membrane 7 front side

(e) Membrane 8 front side

*All images courtesy of Leon Farber,
Merck Center for Materials Science and
Engineering

Figure 3.5 – SEM images of electrical discharge machined
membranes.
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Figure 3.6 shows a process flow diagram containing the membrane emulsifier.
The dispersed phase (DP) fluid is added to a 20 mL or 50 mL stainless steel syringe. The
syringe plunger is driven by a KDS100 syringe pump (KD Scientific, Boston, MA) with a
maximum linear driving force of 88 N. The desired flow rate is manually entered on the
pump's digital display. The fluid is pumped through 1/8 in. outer diameter Teflon tubing
until it couples to a tee at the entrance to the membrane emulsifier. A pressure transducer
(SPT4V, Invensys, Milpitas, CA) is used to measure the DP static pressure at the same
location.
The continuous phase (CP) is added to a 4 L stainless steel pressure vessel. The
vessel is driven by a pressurized air source which is regulated between 0 and 100 psig.
Upon applying pressure to the vessel, CP fluid is forced through a ball valve, woven filter
and needle valve, all constructed of stainless steel. The ball valve is used to shut off the
flow absolutely, while the needle valve is used in combination with the pressure regulator
to set the desired flow rate. An inline flowmeter (FMTE4, DEA Engineering, Anza, CA)
senses the flow rate, and this reading is recorded at a frequency of 1 Hz by the data
acquisition system (OMB DAQ 56, Omega Engineering, Stamford, CT). The CP travels
through ¼" outer diameter stainless steel tubing until it reaches a tee where the static
pressure is measured as the fluid enters the membrane emulsifier.
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Figure 3.6 – Process flow diagram for XME.

3.1.2 Microscope and optics
A diagram of the microscope system used during membrane emulsification
experiments is shown in Figure 3.7. A standard C-mount 640 x 480 resolution 8-bit
COHU 4915 CCD camera is used to collect video images at a rate of 30 interlaced frames
per second. The camera is mounted on an XYZ linear translation stage, providing two
inches of travel in each direction. Light is focused on the camera's detector by a set of
one inch diameter achromat lenses. The upper lens with a focal length of 150mm is fixed
in place at the end of a six inch lens tube. The lower lens is interchangeable, and lens
with focal lengths of 35 mm, 50 mm, 75 mm, 150 mm, or 300 mm were used throughout
the study, thus providing magnification levels of 4.3x, 3x, 2x, 1x, or 0.5x.
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Figure 3.7 – Diagram of microscope system used during membrane
emulsification experiments.

3.1.3 Computer and Data Acquisition System
Analog video from the COHU camera is digitized through a USB video link
connector. Video images are collected using Video Toolbox (version 1.65, Zarbeco,
Randolph, NJ), processed using VirtualDub (version 1.6.19, virtualdub.org), and
analyzed using ImageJ (version 1.38x, rsb.info.nih.gov) and Matlab (R2007a, The
Mathworks, Natick, MA). The Video Toolbox software timestamps each image with the
date and time, using the system clock as the time source. Video exists as a sequence of
uncompressed TIFF gray-scale images. All files are recorded to the system hard drive
with the file name "date_fluid-system_magnification_file-number.avi".
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The image length scale for each lens set is calibrated by imaging a standard
micrometer slide or standard ruler in several different orientations and locations. Using
ImageJ, a line is placed on the image of the slide perpendicular to the hash marks, then a
line intensity profile is generated, thus generating a graph with peaks corresponding to
the center of each hash mark. The average distance in pixels is then compared to the
actual distance in microns, and thus the calibration ratio is determined.
Table 3.2 – Scale calibration factors for lenses used to view XME.

FOV FOV
Scale
Line
Line
Focal
y
x
Ratio
Length Length Length
(µm) (pixels) (µm/pixel) (mm) (mm)
Mag. (mm)
0.5
300
1000
87
11.494
7.4
5.4
1
150
3000
439
6.834
4.4
3.2
2
75
1000
275
3.636
2.3
1.7
3
50
1000
407
2.457
1.6
1.1
*FOV = Field Of View
The OMB-DAQ 56 data acquisition system collects data from various sensors,
then digitizes and imports the data into Microsoft Excel. The program is set up to collect
one datum point each second from the CP and DP pressure transducers, the CP flow
meter, and the ambient and process temperature sensors. Calibration parameters are
shown in Table 3.3.
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Table 3.3 – Sensor calibration values.

System / Parameter
DP Pressure
Scale
Offset
CP Flow
Scale
Resolution
Edge
CP Pressure
Scale
Offset

Value

Units

7.5 psig/V
-7.5 psig
1.173 mL/min/Hz
5 ms
rising
1.673 psig/V
-1.673 psig

3.2 Continuous Phase and Dispersed Phase Fluid Preparation
3.2.1 Simple Systems
In some work, simple binary systems are used for the CP and DP. Typically,
deionized (DI) water is used as the CP (18 MΩ/cm, Easypure Barnstead), and a variety of
fluids are used for the DP. Some examples are n-butanol, n-pentanol, n-hexanol, ndecanol, dichloromethane, ethyl acetate, and their mixtures. All chemicals are obtained
through Fisher Scientific (Fairlawn, NJ) or Sigma (St. Louis, MO). Each phase is
saturated with the opposite phase and allowed to equilibrate overnight, so as to minimize
mass transfer during emulsification.

3.2.2 Complex Systems
When generating drug-loaded polymer microspheres, the DP consists of the
solvent dichloromethane (DCM), the biodegradable polymer poly(D,L-lactide-coglycolide) (PLG), and haloperidol as a model drug. DCM was obtained from Fisher
Scientific (Fairlawn, NJ). PLG (50:50 D,L-lactide/glycolide, ester terminated, inherent
viscosity = 0.82 dL/g in HFIP) was obtained from Birmingham Polymers (Pelham, AL).
Haloperidol was obtained from Sigma (St. Louis, MO). The CP consists of the surfactant
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poly(vinyl alcohol) (PVA) dissolved in DI water. PVA (22 kDa, 88% hydrolyzed) was
obtained from Acros Organics (New Jersey, USA).
For the production of polymer microspheres, CP is prepared by dissolving PVA in
warm DI water at a concentration of 1% by weight. After dissolution of the PVA, the
solution is filtered through a 14 μm cellulose acetate filter and allowed to cool to room
temperature. DP is prepared by mixing haloperidol, PLG, and DCM in a closed container
overnight. In most experiments, the DP contains 9% PLG and 1% haloperidol on a
weight basis. In some experiments, the concentrations are raised to 11% PLG and 1.2%
haloperidol, in order to raise the DP viscosity and increase resistance to droplet rupture.

3.3 Physical Property Measurements
3.3.1 Viscosity
Capillary viscometry is used exclusively for measurement of fluid shear viscosity.
Viscometers with two different capillary diameters are used, type 0C and type 2 (Cannon
Instrument Co., State College, PA). The viscosity is measured by drawing the fluid
through the narrow capillary, then measuring the time required to pass between two
timing lines. The viscosity µ is calculated as µ = kρt, where k is provided by the
viscometer manufacturer, and ρ is the mass density. In this case, k = 0.002665 mm2/s2 or
0.09849 mm2/s2 for the type 0C and type 2 viscometers, respectively. The ambient
temperature is recorded but not actively controlled. Typically, experiments are run in
triplicate, and the average value is reported.
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Big Bulb/Reservoir

Figure 3.8 – Ubbelohde viscometer.

3.3.2 Density
The mass density of different fluids is measured by weighing the quantity of fluid
required to fill a 50 mL volumetric flask to its fill line. The mass density ρ is calculated
as ρ = m/V, where m and V are the mass and volume, respectively. Experiments are
typically run in duplicate, and the average value is reported.

3.3.3 Interfacial Tension
The interfacial tension between the CP and DP fluid phases is measured using two
different methods, namely, pendant drop profile analysis (PDPA) and the drop weight
method. Each method, however, uses the same instrument set up, which is shown in
Figure 3.9.
From Syringe pump
Quartz cuvette

CCD Camera

1/2X Mag.

Stainless steel needle

Adjustable stage Diffuser & Light source

Figure 3.9 – Instrument set up used for interfacial tension
measurements.
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3.3.4 Pendant Drop Profile Analysis
Before beginning, the phases are equilibrated in contact with each other. As
shown in Figure 3.9, a syringe pump is used to drip the DP into the CP at a controlled
rate, generally from a needle tip. However, droplets can also be formed through a
membrane pore, and the analysis works equally well.
recorded.

Videos of the dripping are

Image processing starts from high contrast images of attached droplets,

thresholding and converting the image from 8-bit to binary, then finding the edge
coordinates as well as the drop apex in the image matrix. A coordinate transformation is
then made to convert the drop apex to the zero position, and a scaling factor is added to
give the coordinates proper SI units. Figure 3.10 shows this graphically.

Figure 3.10 – Coordinate system for pendant drop profile analysis.

The edge coordinate array is then fit to the axisymmetric Laplace equation expressed in
cylindrical coordinates1,
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Δp = γ∇ ⋅ nˆ

(3.1)

r = c( z )

(3.2)

⎤ ⎡ ⎛ dc ⎞ 2 ⎤
p − p − ρ − ρ g (H − z ) = ⎢c 2 − ⎜ ⎟ − 1⎥ ⎢1 + ⎜ ⎟ ⎥
c ⎢⎣ dz ⎝ dz ⎠
⎥⎦ ⎢⎣ ⎝ dz ⎠ ⎥⎦
B
H

A
H

(

A

B

2
γ ⎡ d 2 c ⎛ dc ⎞

)

−3 / 2

(3.3)

This expression can be non-dimensionalized to result in
2
⎤ ⎡ ⎛ dc * ⎞ 2 ⎤
1 ⎡ d 2 c * ⎛ dc * ⎞
− G + z* =
−⎜
⎟ − 1⎥ ⎢1 + ⎜
⎟ ⎥
⎢c *
c * ⎢⎣ dz *2 ⎝ dz * ⎠
⎥⎦ ⎢⎣ ⎝ dz * ⎠ ⎥⎦

−3 / 2

(3.4)

with the dimensionless variables defined as

[

][

G ≡ p HA − p HB + (ρ A − ρ B )gH γ (ρ A − ρ B )g
⎡
⎤
γ
x* = x ⎢ A
⎥
B
⎣ ρ −ρ g⎦

(

]

−1 / 2

(3.5)

−1 / 2

)

(3.6)

and the boundary conditions
z* = 0 ⇒ c* = 0

z* → 0 ⇒

dc *
→∞.
dz *

(3.7)

(3.8)

The Laplace equation expressed above has only two unknowns, γ and ΔpH = pHB –
pHA, once the densities of each phase and the drop contour r = c(z) are known. Using a
non-linear least squares optimization routine, we solve for γ and ΔpH, then use these
values to calculate G. This procedure is performed for each half of the drop, and the
average of the two values is reported along with the sum of the squared errors. An
example starting image and resultant drop are shown in Figure 3.11 and Figure 3.12.
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Figure 3.11 – Drop of 1-pentanol in water attached to 90 µm pore.

Figure 3.12 – Laplace equation fit (solid line) to 1-pentanol image
edge coordinates (diamonds). The calculated interfacial tension γ =
4.7 mN/m is similar to the literature result2 of γ = 4.4 mN/m ± 0.2
mN/m. Also shown are the differential pressure inside and outside the
drop at the apex, p, the sum of squared errors, SSE, the shape
parameter, G, the drop volume, V, and the drop surface area, S.
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Using the edge coordinate array, the volume of the drop, V, is calculated using the
formula for a solid of revolution
V = π ∫ [c( z )] dz
H

2

(3.9)

0

and the surface area, S, is calculated similarly using

S = 2π ∫

H

0

2

⎛ dc ⎞
c( z ) 1 + ⎜ ⎟ dz .
⎝ dz ⎠

(3.10)

Because movies are shot instead of individual images, it is possible to determine
the reproducibility of interfacial tension measurements over time using an individual drop
or multiple drops.

Similarly, when surfactants are present in the system, the drop

dynamic interfacial tension can be measured as additional surfactant is adsorbed to the
interface. Because the PDPA technique assumes that the drop is static, low flow rates
must be used if systemic errors are to be avoided. Figure 3.13 shows drop volumetric
flow rate and interfacial expansion rate as a function of time for eight individual drops,
with time zero defined as the point of drop snap off for the previous drop. Figure 3.14
shows average interfacial tension (n = 11) and relative standard deviation (RSD) across
the same data set. As can be seen, the method is noisy for young drops, as measured by
the RSD. This is due to the small deformations in young drops, which results in highly
spherical drops, a consequence of the small ratio of gravitational to interfacial forces.
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Figure 3.13 – Volume and surface expansion rates during PDPA.
These values are calculated for dispersed phase of a 9% solution of
PLG in dichloromethane being pumped into a continuous phase of 1%
poly(vinyl alcohol) in water. The flow rate set point is 11.0 mL/hr and
the needle size is 460 µm.
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Figure 3.14 – Average interfacial tension (n = 11) (pink open
squares) and associated relative standard deviation (blue closed
diamonds) during PDPA. The values are calculated from a series of
images of 9% PLG in dichloromethane being dripped into a continuous
phase of 1% poly(vinyl alcohol) in water. The flow rate set point is
11.0 mL/hr and the needle size is 460 µm.

3.3.5 Drop Weight Method
Before beginning, the phases are equilibrated in contact with each other. As
shown in Figure 3.9, a syringe pump is used to drip the DP into the CP at a controlled
rate. Videos of the dripping are recorded. Droplet size is measured starting from high
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contrast images of detached droplets, thresholding and converting the images to binary,
then finding the edge coordinates, and numerically integrating the volume of the droplets
by assuming axisymmetry.
The interfacial tension is determined using the Harkins and Brown methodology34

. A simple force balance predicts that the weight of a drop that falls from a needle tip is

related to the interfacial tension according to

πD0 γ = Δρg

π
6

D3

(3.11)

However, this expression only holds true in the limit of D0 → 0, due to non-linear effects
that occur during droplet snap-off. For finite D0, it was shown by Harkins and Brown3
that an empirical correction factor could be found. Yildrim et al.4 refined this approach
to a simple correlation
Bo = 3.60Φ 2.81

(3.12)

where the Bond number Bo = ΔρgD02/4γ and Φ is the dimensionless drop size Φ =
0.62D0/D. This expression can be further manipulated to yield

γ = 0.266ΔρgD02 (D / D0 )2.81 .

(3.13)

Thus the interfacial tension γ between the two fluid phases can be calculated once the
diameter D of the drop that falls is measured, assuming the density difference Δρ between
the phases, gravitational acceleration g, and the needle diameter D0 are known. Because
the drops that fall are deformed due to gravity and hydrodynamic forces, the equivalent
spherical diameter D is calculated from the volume V of the droplet according to
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⎛6 ⎞
D=⎜ V⎟
⎝π ⎠

1/ 3

.

(3.14)

Generally speaking, the interfacial tension is a function of the time scale over
which the measurement is performed. When using the drop weight method, we are
interested in how the interfacial tension varies with the drop period Δt. The drop period
is simply

Δt =

π D3
6 QDP

.

(3.15)

The volumetric flow rate is calculated by measuring the drop volume and the time
between drop detachments, and this flow rate is compared to the set point of the syringe
pump in order to assure that the process is at steady state.
In order to measure interfacial tension using this method, the flow stream must be
dripping and not jetting, thus implying We ≤ O(1), where O(1) means a number on the
order of 1. This occurs for

QDP

⎛ π 2 γD03
≤ ⎜⎜
⎝ 8 ρ DP

⎞
⎟
⎟
⎠

1/ 2

.

(3.16)

Setting We = 1 and then combining these relationships provides the appropriate scaling
relationship for how droplet period changes with needle size:
⎛ ρ ⎞
Δt = 0.5D ⎜⎜ 3 ⎟⎟
⎝ γD0 ⎠
3
0

0.5

1.07

⎛ γ ⎞
⎜⎜
⎟
2 ⎟
⎝ ΔρgD0 ⎠
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~ D0− 0.635 .

(3.17)

This implies that as the needle diameter grows larger, the droplet period decreases. But
in order to maintain We constant, the volumetric flow rate must be increased quickly,
with QDP ~ D01.5. Figure 3.15 depicts these results.
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Figure 3.15 – Calculated drop period and corresponding flow rate
to maintain We = 0.1. Calculations are for a fluid system with Δρ =
330 kg/m3 and γ = 8 mN/m.

3.3.6 Contact Angle Analysis
Contact angles of the various fluids against strips of stainless steel are measured
by first cleaning the membranes via sonication in a 1% Alconox solution, then thoroughly
rinsing and drying. The strips are then placed into a medium of one fluid, and the second
fluid is dripped onto the surface of the strip. The process is recorded using the video
microscope, and the contact lines are observed until equilibrium is reached.
Subsequently the images are analyzed via the DropSnake ImageJ plugin5, which utilizes
Laplace's equation to find the contact angle which results in the best fit of the drop
contour. Depending on the preference for the outer phase (CP), either Method #1 or
Method #2 is used, shown in Figure 3.16. Independent of which fluid is selected as the
CP, the contact angles in these two methods should be related according to θDP/SS = 180°
– θCP/SS.
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g

Method #1
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Figure 3.16 – Schematic of pendant or sessile drops during contact
angle experiments. The drops are attached to needle tips prior to
dripping onto a stainless steel substrate.

Figure 3.17 – Inverted image of water + 1% PVA on SS in a
medium of DCM.

3.4 Preliminary Results from Physical Property Measurements
3.4.1 Interfacial tension measurements of normal alcohols
The interfacial tension of n-alcohols against water were measured by Villers and
Platten2 as a function of temperature using the Wilhelmy plate method, and these results
are used for comparison to the PDPA results derived within this work. Figure 3.18 shows
the reported values of Villers and Platten for different n-alcohols containing between 4
and 12 carbon atoms (solid line), as well as our results (diamonds). The data are
comparable, with the largest difference being for decanol, where the difference is about
10%.

This difference could be caused by system impurities or subtle temperature

differences. Regardless, the differences across the range of compounds are small enough
to conclude that the PDPA data are generally accurate.
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Figure 3.18 – Comparison of experimental and reported values of
interfacial tension at 20°C.

3.4.2 Physical properties of binary solutions of n-hexanol and
dichloromethane
When examining the behavior of different fluids in the XME process, it is
convenient to be able to tune physical properties through mixing two pure fluids. As a
DP, n-hexanol and dichloromethane have disparate properties, and thus display
drastically different dynamics during dripping-jetting transitions and droplet snap off in
XME. Thus their mixtures are used to probe the transition between the different physical
regimes. The physical properties of the mixtures as a function of weight percentage of
DCM are shown in the four plots contained within Figure 3.19, with the solid lines
generated by applying a weighted average to the values for the pure components. The
density and viscosity of the mixtures show negative deviations from the interpolated
predictions, which could be caused by a repulsive force between the two component
molecules. The interfacial tension against water, measured via PDPA, also shows a
negative deviation, and the trend also shows strange curvature. For this reason, replicate
experiments were conducted, with the error bars indicating the standard deviation. The
error bars show that the data are reproducible, and any error must be systematic in nature.
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It is likely that some systematic error is introduced because the density of the solution is
near that of water, and this reduces the accuracy of the PDPA technique. The fourth plot
in Figure 3.19 shows the Ohnesorge number, Oh = µ/(ρD0γ)1/2, with D0 = 90 µm, as a
function of concentration, and it can be seen that a wide range of Oh are accessible
through the use of binary hexanol-DCM mixtures.
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Figure 3.19 – Physical properties of mixtures of n-hexanol and
dichloromethane.

3.4.3 Viscosity of polymer solutions
When used as the dispersed phase in XME, the shear viscosity of the polymer
solution has an appreciable impact on both the physics of droplet formation and break
off, and also on the stability of droplets during downstream processing.

46

For these

reasons, we measure the relationship between polymer concentration and shear viscosity
for both a binary solution of PLG in DCM, and a PLG:haloperidol in DCM ternary
system. Measurements are performed using capillary viscometry. Using the values
obtained for the shear viscosity of both the pure solvent η0 and the polymer solution η at a
given polymer concentration c, we can calculate a number of other useful parameters that
are widely used throughout the polymer literature. Table 3.4 gives the definitions of
these terms.
Table 3.4 – Definitions of viscosity terms.

Parameter

Definition

Relative viscosity

η rel =

Reduced viscosity

η red =

Inherent viscosity
Intrinsic viscosity

η
η0
ηrel − 1

c
ln(η rel )
η inh=
c
[η ] = limη inh= limη red
c →0

c →0

Utilizing these definitions, we calculate both the inherent viscosity ηinh and reduced
viscosity ηred as a function of polymer concentration. At low concentrations, these
relationships are both predicted to be linear. Figure 3.20 shows that this is indeed the
case for the binary system. Both curves are predicted to intercept the y-axis at the
intrinsic viscosity, [η], which we measure to be 57.3 mL/g.

The polymer overlap

concentration, c*, is approximately equal to the reciprocal of this value, c* ≈ 1/[η] =
0.0175 g/mL. The slope of the reduced viscosity curve is [η]2k', where k' is called the
Huggins' coeffiecient. For this system, k' = 0.44, and this value indicates that DCM is

47

neither a good solvent for PLG (0.3 < k' < 0.4) nor a theta solvent (0.8 > k' > 0.5), but
rather is between these two extremes6.
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Figure 3.20 – Viscosity dependence on polymer concentration for
PLG dissolved in DCM.

Above c*, ηred is often observed to rise exponentially in accordance with the Martin
equation

η red = [η ]exp(kc[η ]) .

(3.18)
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Figure 3.21 – Shear viscosity dependence on polymer concentration
for PLG dissolved in DCM.

In Figure 3.21, we plot the shear viscosity as a function of polymer concentration,
and fit the data to the Martin equation using a non-linear least squares regression. The
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data fit well, despite the fact that only one fitting parameter is used. Also shown on the
plot are viscosities of the PLG:haloperidol 9:1 ternary solution. The viscosities are
similar, but systematically lower than the predictions for the binary system, most likely
due to small temperature differences during the two experiments.

3.4.4 Zimm theory
In some experiments it is desirable to predict the polymer relaxation time λ while
in solution. In particular, this prediction is relevant to the dynamics of droplet neck snap
off, where polymer molecules are elongated due to the high elongational stresses in the
flow. Zimm theory predicts that for dilute solutions, λ is related to the polymer and
solution properties by

λ=

6[η ]η0 M w
π 2 RT

(3.19)

where Mw is the polymer molecular weight (Mw = 137 000 g/mol for the PLG grade used
here), and R and T are the gas constant and system temperature, respectively.

At

concentrations higher than the dilute limit, this relation is often used as an estimate of λ,
with the solvent viscosity η0 replaced by the solution viscosity η.7 The relaxation time in
a standard 90% DCM, 9% PLG, and 1% haloperidol solution can then be estimated to be
λ = 3 x 10-5 s. By doubling c, we predict an increase from η = 15 mPa-s to 240 mPa-s,

which would result in λ = 5 x 10-4 s, a 17-fold increase.

Similarly, by keeping

concentration constant but instead doubling the molecular weight so that Mw = 274 000
g/mol, we predict that [η] = 90 mL/g and η = 73 mPa-s. Coincidently, this would also
lead to λ = 5 x 10-4 s. During a typical XME experiment using this ternary system, the
strain rate is found to be ε& = 2400 s-1, implying that the typical system will not exhibit
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elastic effects, but that elastic effects should be found at higher Mw or c because De = ε& λ
> 1. These results are further discussed in Chapter 4.

3.5 Sizing of Microspheres
In most experiments, the droplets produced via XME are deformed from a sphere
and into a prolate spheroid due to the shear stress imposed by the flowing CP. This
complicates slightly the measurement of particle size. The diameter of a droplet is
measured in two ways.

In the simplified method, the major and minor diameters are

measured manually in ImageJ from a video frame containing the droplet image. When
higher resolution and/or larger sample sizes are needed, an automated image analysis
routine in Matlab processes image sequences such that an ellipse can be fit to the droplet
perimeter. This image analysis process is similar to what is used for interfacial tension
measurements. Specifically, droplet images are converted to binary, thresholded, and the
droplet edge coordinates are determined, from which the major and minor diameters and
angle of rotation are determined. In all cases, the reported diameter is calculated as the
average of the major and minor diameters. While an assumption that the particle takes
the shape of a prolate spheroid with equivalent spherical diameter D = (Dminor2Dmajor)1/3
may be more appropriate for highly deformed particles, for the small deformations seen
here the result is indistinguishable from this and other advanced diameter calculation
techniques.

3.6 Downstream Processing of Drug and Polymer Loaded
Emulsion Droplets
The classical oil-in-water emulsion-solvent evaporation method is used in
preparation of solid microspheres8. After production of the emulsion droplets via XME,
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they are collected in a large vessel and allowed to settle under gravity. Only gentle
agitation is used so as to prevent shear break up of the particles. Over a period of many
hours, DCM is slowly extracted into the CP, where it is sparingly soluble (solubility of 13
g/L in pure DI water at 20°C). The DCM is then readily evaporated from the collection
vessel due to its low boiling point (vapor pressure of 47 kPa at 20°C), yielding solid
drug-loaded polymer microspheres. These solid microspheres are then isolated from the
suspending medium by filtration, and in the process are washed with pure DI water to
eliminate residual PVA.

3.7 Computational Fluid Dynamics
Two software programs, Fluent 6.3 and Gambit, are used to perform
Computational Fluid Dynamics (CFD) simulations of the membrane emulsifier CP flow
and the emulsification process.

3.7.1 Continuous Phase Flow Simulations
Although the velocity profile for fully developed laminar flow in a rectangular
channel can be found analytically, it is difficult to assess whether flow is full developed
when it passes the membrane pore. CFD simulations of the velocity in the entire CP flow
channel as a function of the total flow rate QCP yield the results shown in Figure 3.22. In
the simulations, ρ = 1020 kg/m3, µ = 0.0034 kg/m/s, and the simulation is set up using
steady state, three dimensional, double precision, pressure-based Navier-Stokes equation
in laminar flow. Boundary conditions are constant velocity at the inlet, and constant
pressure at the outlet, with no slip at the chamber walls. As can be seen, flow profiles at
the y-z plane x = 0 are fully developed and symmetric for QCP = 10 mL/min and QCP =
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100 mL/min, whereas at QCP = 1000 mL/min the flow is no longer well behaved.
Consequently, experiments are conducted such that QCP < 300 mL/min.

(a) Top View – 10 mL/min

(b) Front View – 10 mL/min

(c) Top View – 100 mL/min

(d) Front View – 100 mL/min

(e) Top View – 1000 mL/min

(f) Front View – 1000 mL/min

Figure 3.22 – Contours of velocity magnitude (m/s) calculated in
Fluent 6.3. Flow is in +x-direction.
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3.7.2 Cross-flow membrane emulsification simulations
Simulations of the cross-flow membrane emulsification process are performed to
further validate experimental and theoretical results.

In the simulations, the

computational mesh is set up with the following properties:
•
•
•
•

CP Zone (x by y by z) = 6.35 mm by 3.175 mm by 3.175 mm
DP Zone (diameter by length in y) = 0.090 mm by 0.3048 mm
Single x-y symmetry plane at pore midline z = 0
Number of cells = 6 x 105

Figure 3.23 – Computational mesh used for CFD simulations of
membrane emulsification.

Fluid properties used in the simulations are shown in Table 3.5. Through the
simulations, the CP volumetric flow rate QCP is varied, while the DP flow rate QDP is held
constant. Simulation boundary conditions are constant velocity at both inlets, constant
pressure at the outlet, and a contact angle of 180° between the DP and the chamber walls.
Figure 3.24 shows typical results.
Table 3.5 – Physical properties of fluids in Fluent simulation.

Chamber Properties
D0
H
W
(µm) (mm) (mm)
90
3.18
6.35

DP Properties

ρ

μ

CP Properties

ρ

μ

(kg/m3) (kg/m/s) (kg/m3) (kg/m/s)
1326.5 0.000437 1000
0.00125
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CP/DP

γ

(kg/s2)
0.0061

Figure 3.24 – Volume fraction contours shown at the symmetry
plane during a cross-flow membrane emulsification simulation. In
this simulation, QCP = 50 mL/min and QDP = 5.1 mL/hr.

3.7.3 Cross-flow membrane emulsification simulation results
Simulations are performed across the range 50 mL/min < QCP < 400 mL/min, and
all at QDP = 5.1 mL/hr. In each case, the simulation is run until a droplet breaks off from
the membrane pore. The image is then analyzed to determine the diameter of the droplet.
The dimensionless droplet size D/D0 is plotted against the capillary number,

Ca = μCP

dv
D0 γ .
dz

A regression line fit to the data yields the form D/D0 = kCa-0.5, with k = 0.42.
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(3.20)
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Figure 3.25 – Dimensionless droplet diameter vs. capillary number
from Fluent simulations.

3.8 Model Drug Haloperidol
Haloperidol is a popular drug indicated for use in the management of psychotic
disorders, as well as for the control of tics of Tourette's Disorder9. It is an excellent
model drug for use in microencapsulation studies due to its low daily dose and high
hydrophobicity10. Furthermore, because the drug has been studied since at least 196011, it
has been the subject of numerous investigations12-17, and physical and chemical properties
are widely available. For these reasons, haloperidol is used throughout the present
studies.

Figure 3.26 – Haloperidol molecular structure.
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Table 3.6 – Physical and chemical properties of haloperidol.

Property
Molecular weight11
Crystalline melting point (free base)11
Water solubility at pH = 7.4 and room temperature17
Water solubility at pH = 6.0 and room temperature17
pKa17
Peak UV absorbance18
Extinction coefficient at 244 nm18
Typical oral dose range (BID or TID)9
Elimination half-life19
Relative bioavailability19

Value
375.86
148
15
201
8.25
244
0.0341
0.5 – 5.0
15.1 ± 2.5
0.64 ± 0.23

Units
g/mol
°C
mg/L
mg/L
nm
L/mg/cm
mg
hr

3.9 In Vitro Drug Release Measurement System
A dual reactor and flow system coupled to a dual inline spectrophotometer are
used to measure drug release from polymer particles over time.

The two independent

systems can be used to conduct two release studies simultaneously, or one can be used as
a control or to continuously monitor background absorbance. These components are
described below.

3.9.1 Drug release microenvironment
A Spectra/Por Float-a-lyzer G2 1 mL dialysis device with 100K MWCO cellulose
ester membrane (Sigma-Aldrich, St. Louis, MO) is used to retain the particles in a static
state without convection during drug release studies, which is similar to the physiological
environment particles experience when injected subcutaneously or intramuscularly.8 The
particles are added to the container along with buffer solution, and a screw on cap with oring positively seals the container. A flotation ring surrounds the outside of the device
and thus maintains the device oriented upright at the fluid surface within the stirred tank.
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3.9.2 Reactor and Flow System
Figure 3.27 shows a diagram of the system flow setup, which is designed as
follows. A recirculating controlled temperature water bath sends warm water through
two daisy-chained glass jacketed mixing tanks, thus keeping the vessels at the desired
temperature set point, typically 37°C. The two mixing tanks are typically filled with 900
mL phosphate buffered saline solution, and sometimes a surfactant such as polysorbate
20, and an antimicrobial agent such as NaN3. At the bottom of the tanks are magnetic stir
bars, driven by the magnetic stir plates below. Three through holes are cut into the
custom-made lid for each vessel. A long supply dip tube is located near the bottom of the
vessel. From the supply dip tube, silicone silastic tubing leads to the bottom of the quartz
flow cell so that any air entrained in the system can escape. The top of the flow cell is
connected to Cole-Parmer Pharmed tubing, which is more resilient to continuous use.
The tubing passes through the peristaltic pump, and then leads back to the return dip tube
in the same mixing tank. One ¼ inch diameter type K immersible thermocouple is
located in each tank and is connected to the data acquisition system to provide continuous
temperature monitoring.
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Figure 3.27 – Reactor and flow system used for drug release
studies.

3.9.3 Dual-Channel Spectrophotometer
The dual-channel spectrophotometer shown in Figure 3.28 can be used to measure
the UV absorbance at λ = 250 nm of any solution contained in a standard 1 cm cuvette.
The wavelength of 250 nm is used because there is a maximum in haloperidol absorption
near this value (λmax = 244 nm). Other wavelengths can be selected by replacing the
band-pass filter that follows the collimating lens.
The spectrophotometer is designed as follows. A function generator is used to set
the frequency with which light is produced. Typically, a frequency of 1 pulse per second
is used, and the monostable multivibrator 74HC123 chip is used to stretch the pulse to the
desired width. See Figure 3.29 for the circuit design. The PX-2 UV (Ocean Optics,
Dunedin, FL) light source produces a pulse of wide spectrum UV light when it detects the
rising edge from a 0 to 5 V TTL signal from the peak-hold circuit.
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After being

transmitted through a fiber optic cable, the light is collimated and passed through a 250
nm band pass filter. A polka dot beam splitter (Thorlabs, Newton, NJ) divides the
collimated light beam into two roughly equal beams 90° apart. Each collimated light
beam passes through a quartz cuvette. Glass absorbs UV light and thus cannot be used.
Any absorbing species reduces the amount of light that is transmitted through the cell. A
40 mm focal length lens contained within a 1 inch diameter lens tube focuses each light
beam onto the 2.54 x 2.54 mm active area on the PDA25K photodiode (Thorlabs). The
photodiode, set to a gain of 70dB, sends a 0 to 10 V signal to the LF398 chip on the peakhold circuit. The signal output of the LF398 chip tracks the signal input from the
photodiode as long as the logic input voltage to the chip is 5 V. When the logic input
falls to 0 V, the logic gate closes and the capacitor on the chip holds the signal output at
the voltage read when the falling edge was detected. The monostable multivibrator
74HC123 is used to set the square wave pulse to the desired width, such that the falling
edge corresponds with the peak output from the photodiode. The OMB-DAQ USB data
acquisition module reads the signal output voltage on the LF398 chip and records to a
Microsoft Excel file. The signal output reads the peak of the photodiode signal except
when the TTL signal is at 5 V. Because this only occurs for about 10 µs every second,
this is a rare occurrence. The peak hold circuit shown in Figure 3.29 is used to collect the
photodiode signal and transmit it to the data acquisition device.
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Figure 3.29 – Timing circuit and peak-hold circuit used within the
spectrophotometer.
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The photodiode gives readings in voltage, and the absorbance A is calculated
using
⎛V ⎞
A = log⎜ 0 ⎟
⎝V ⎠

(3.21)

where V is the reading of the sample, and V0 is the reading of the cell with solvent (but no
sample). Beer's Law states that
A = ε i ci L

(3.22)

where εi is the extinction coefficient of species i, ci is the solute concentration, and L is
the cell path length. Using these relationships, the concentration of dissolved species can
be determined from the absorbance readings once the absorption coefficient is known. A
calibration curve generated using numerous dilutions of a 50 mg/L haloperidol in 0.1%
lactic acid aqueous solution shows that Beer's law holds true up to at least c = 50 mg/L,
and the limit of detection for haloperidol is around c = 0.1 mg/L.
10

Spectrometer #1
A = 0.0279c
R2 = 0.9943

Absorbance

1

Spectrometer #2
A = 0.0276x
2
R = 0.9984

0.1

0.01
Spectrometer #2
Spectrometer #1
0.001
0.1

1

10

100

Haloperidol Concentration (mg/L)

Figure 3.30 – Calibration curve of spectrophotometers using
haloperidol.
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3.9.4 Pure haloperidol dissolution experimental results
To test the reactor and flow system, we measure the dissolution of haloperidol in
phosphate buffered saline (PBS) containing 0.02% sodium azide and 1% polysorbate 20
at a temperature of 37°C. Because the system is not closed during the experiment, we
observe significant evaporation from the vessels, which are at elevated temperature. For
this reason, the second parallel spectrometer is used as a baseline throughout the
experiment. The photodiode gives readings in voltage, and the absorbance value is
calculated using A = -log(V1/( V2–V2,0+V1,0)), where V1 is the reading of the sample in
system #1, V2 is the reading of flow system #2, and Vi,0 is the initial reading in each
system. After preparing the solution as described and heating to the proper temperature,
we sprinkle ~100 mg of haloperidol on top of the stirring tank.
The dissolution results are shown in Figure 3.31. The experimental data are fit to
a standard exponential curve
c / c∞ = 1 − exp (− (t − tlag ) / τ )

(3.23)

with c∞ = 9.90 mg/L, tlag = 0 hr, and τ = 4.60 hr. Surprisingly, the experiment did not
show any increase in the equilibrium solubility of haloperidol compared to pure PBS at
37°C, which has previously been measured as ~10 mg/L (data not shown). However, the
rate at which equilibrium is reached is faster than previous experiments. This is likely
caused by improved wetting of the haloperidol particles due to the presence of the
surfactant in the system.
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Figure 3.31 – Haloperidol dissolution into PBS at 37°C with 0.02%
sodium azide and 1% polysorbate 20.

3.10 Mathematics of Fluid Flow Through a Rectangular Channel
Because the CP travels in laminar flow down a long rectangular channel through
the membrane emulsifier, it is important to understand the mathematics that describe the
flow profile. Figure 3.32 describes the geometry.
z
y

H = 2b

W = 2a
Figure 3.32 – Geometry of a rectangular channel.

For Newtonian fluids in fully developed laminar flow, solving the Navier-Stokes
equation results in the following expression for the fluid velocity vx in the x-direction as a
function of position in the y and z directions.
(i −1) / 2

∞
v x ( y, z )
= ∑ (− 1)
vmax
i =1, 3, 5 ,...

⎡ cosh (iπz / 2a ) ⎤ cos(iπy / 2a )
⎢1 − cosh (iπb / 2a ) ⎥
i3
⎣
⎦
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(3.24)

However, because of the slow convergence of this infinite series, it is much more
convenient to work with an approximate solution.

Purday proposed the following

expression20
2
α
v x ( y, z ) ⎡ ⎛ z ⎞ ⎤ ⎡ ⎛ y ⎞ ⎤
= ⎢1 − ⎜ ⎟ ⎥ ⎢1 − ⎜ ⎟ ⎥
vmax
⎢⎣ ⎝ b ⎠ ⎥⎦ ⎢⎣ ⎝ a ⎠ ⎥⎦

(3.25)

with the parameter α defined as

W
H 2
⎧
⎪1.54 H , 0 ≤ W ≤ 3
α =⎨
.
2 H
⎪ 2.3,
≤
≤1
3 W
⎩

(3.26)

The maximum velocity vx can be related to the total volumetric flow rate QCP through
integration

QCP = 4vmax ∫

a

0

∫

b

0

⎡ ⎛ z ⎞ 2 ⎤ ⎡ ⎛ y ⎞α ⎤
⎢1 − ⎜ ⎟ ⎥ ⎢1 − ⎜ ⎟ ⎥ dzdy
⎣⎢ ⎝ b ⎠ ⎦⎥ ⎣⎢ ⎝ a ⎠ ⎦⎥

(3.27)

which yields

vmax =

3 ⎛ α ⎞ QCP
⎜
⎟
2 ⎝ α + 1 ⎠ HW

(3.28)

To test the accuracy of the Purday approximation, we plot both the full solution
and the approximate solution at the channel center for the two different channel heights
used in this research, and Figure 3.33 is the result. As can be seen, there are only
negligible differences in the two equations for the set of parameters studied here.
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Figure 3.33 – Velocity profiles calculated for flow in a rectangular
duct. Solid lines give the profile from the full analytical solution,
while dotted lines give the approximate solution of Purday. Shown are
the velocity profiles for the two channel heights used in our study, b =
H/2 = 1.59 mm and b = 0.50 mm.

Ultimately, we are interested in the shear rate at the membrane pore, which can be
calculated through differentiating the velocity profile from the Purday equation
6Q ⎛ m + 1 ⎞
⎛ dv ⎞
= 2CP ⎜
⎜ ⎟
⎟
⎝ dz ⎠ pore H W ⎝ m ⎠

(3.29)

For the special case of 1 < W/H < 3, an alternate expression for the shear rate was derived
from the full analytical solution, and this expression in included here for completeness.
9.7Q
⎛ dv ⎞
= 1.67 CP1.33
⎜ ⎟
⎝ dz ⎠ pore H W

(3.30)

Either expression can be used within the specified limits, but in general the expression
derived from the Purday equation is preferred due to wider applicability.
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Chapter 4: Universal dripping and jetting in a transverse
shear flow
One particularly efficient approach to making emulsions having mono-sized
droplets is to push a fluid through an orifice into a transverse flow of a second immiscible
fluid. We find that at intermediate particle Reynolds number, the final droplet size can be
readily computed using a simple force balance. Remarkably like the well-known dripping
faucet, this system displays both dripping and jetting behavior, controlled by the
capillary, Weber and Ohnesorge numbers of the relevant fluids, and interesting non-linear
behavior such as period doubling near the transition between these two regimes.

Appeared in Physical Review Letters, by Robert F. Meyer and John C. Crocker, Vol. 102, Article 194501,
12 May 2009. © 2009 by The American Physical Society.
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4.1 Introduction
Drop formation and breakup have long been an object of interest due to the
surprising complexity of the phenomena1. Breakup occurs either by an external force
tearing a growing drop from an orifice, as in the dripping faucet, or at higher flow rates,
by the breakup of a jet emerging from the orifice, as in the Rayleigh instability2. Near the
transition between dripping and jetting, drop formation shows interesting non-linear
dynamics, including period doubling and chaos3-4. More recent studies have probed drop
formation in several microfluidic geometries, such as coaxial flow5-6 and T-junctions7,
where controlled droplet formation is an important technological problem.
Here, we study droplet formation in a cross-flow membrane emulsification
(XME) geometry, a high-throughput method for generating mono-disperse droplets8-10. In
XME, the dispersed phase (DP) is forced through an orifice in a planar membrane into a
simple shear flow set up by a second continuous phase (CP) flowing parallel to the
membrane surface, see Figure 4.1(a). In the dripping regime, when buoyancy forces are
negligible11, the final droplet diameter, D, results from the competition between
hydrodynamic stresses proportional to the CP shear rate, dv/dz, and forces from the
interfacial tension, γ. This leads us to introduce the capillary number, which is a ratio of a
drag force, μCP(dv/dz)D02, and an interfacial tension force, γD0: Ca = μCP(dv/dz)D0/γ,
where μ is the viscosity and D0 the orifice diameter. At high DP flow rates, the inertial
force of the fluid emerging from the orifice, ρDPQDP2/D02, exceeds the interfacial tension
force, leading to a transition to jetting behavior, where Q is the volumetric flow rate and

ρ the mass density. The ratio of these forces is the Weber number: We = ρDPQDP2/D03γ.
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We find that the droplet size in the dripping regime scales with the applied forces in a
manner different from those in the dripping faucet and coaxial flow geometries, but that
the transition between dripping and jetting is remarkably similar. This latter point is more
surprising given the lack of axial symmetry in our system.

4.2 Methods
Our experimental apparatus consists of a long rectangular channel with height H =
3.2mm and width W = 6.4mm through which the CP flows. The DP is forced through a
single circular pore (D0 = 15, 90 or 132µm) on the centerline of the bottom wall, using a
syringe pump. Drop formation is monitored from the side, with a viewing angle ≈ 7°
above the membrane plane, using a long-working distance video microscope. A pair of
right angle prisms straddling the channel redirects illumination and viewing light through
a window at the top of the channel. Several fluids were used for the DP, listed in Table
4.1, while the CP was limited to water, sometimes with poly(vinyl alcohol) (PVA) as a
surfactant. For each system studied, the two fluids were equilibrated in contact, so as to
minimize mass transfer during the experiment. The densities ρCP and ρDP, viscosities μCP
and μDP and interfacial tension γ for each equilibrated combination were measured
directly by mass, capillary viscometry and pendant drop profilometry12, respectively (cf.
Table 4.1).
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Table 4.1 – Liquids used and some of their physical properties at 18°C. Mixture proportions are given
in w/w. Small, medium and large symbols represent a D0 of 15, 90 or 132µm, respectively.

Symbol
Dispersed Phase
ρDP
μDP
γ
3
(surfactant)
(kg/m ) (mPa s) (mN/m)
n-butanol
827
3.31
2.4
n-pentanol
817
3.61
4.8
n-hexanol
809
5.06
6.3
a
871
3.12
7.5
DCM + hexanol 20/80
DCM + hexanol 40/60
943
1.79
9.7
DCM + hexanol 60/40
1039
1.14
9.1
DCM (0.05% PVA)
1320
0.44
12.0
DCM (0.50% PVA)
1320
0.44
6.1
1320
0.44
6.1
DCM (0.50% PVA)b
ethyl acetate
902
0.50
6.5
a
dichloromethane, bcomputational fluid dynamics simulation15

4.3 Qualitative results
The qualitative features of the dripping and jetting behavior in XME are shown by
the images in Figure 4.1, taken at a constant Ca. At low Weber number, We = 0.5, simple
dripping is observed, Figure 4.1(b-d). Because the interfacial force is dominant, the
droplet is able to grow reproducibly each cycle until detached by the flowing CP. At We
= 1.1, the location of droplet snap-off moves away from the orifice, but the size of the

resultant droplet remains roughly the same, Figure 4.1(e-g). The momentum of the
flowing DP distends the droplet neck noticeably; for these parameters the distended neck
also snaps-off reproducibly to form a satellite droplet. Increasing the DP flow rate further
by 20%, We = 1.6, causes further extension of the droplet neck, with multiple peaks and
nodes observed, and a noticeable decrease in droplet size, Figure 4.1(h-j). An additional
10% increase in QDP, We = 2.0, leads to a stable bifurcation of the resultant droplet size,
where the elongated neck/jet alternates production of small and large droplets, Figure
4.1(k-m). These and more complex non-linear dynamical behavior (not shown) were
observed near the transition, over the entire range of different Ca we studied.
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Figure 4.1 – Dripping and jetting at various We for Ca = 8 x 10-4
and OhDP = 4 x 10-2, variables defined in text. (a) Cartoon
representation of the XME process, where droplets of dispersed phase
(DP) are torn from an orifice by a simple shear flow in the continuous
phase (CP). At low DP flow rates, monodisperse drops form and break
off near the pore (b-d); scale bar = 500 µm. As the DP flow is
increased, first droplets are the same size, but move away from the pore
prior to snap-off, forming satellite drops (e-g). Eventually, the fluid
neck lengthens further and droplet sizes decrease (h-j). Ultimately, a
bent fluid jet breaks into droplets, exhibiting period doubling (k-m).

4.4 Development of droplet size model
Given the interest in using XME to produce monodisperse emulsions, we first
seek to understand the particle size in the dripping regime (i.e. low We), as a function of
the hydrodynamic stress due to the shear flow; typical data are shown in Figure 4.2(a).
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For all systems studied, the droplet diameter scales as D ∝ (dv/dz)-1/2. This square root
dependence has a simple physical origin. In our geometry, the mean velocity of the fluid
at the drop center is itself proportional to the droplet size, as larger droplets poke up
higher to impinge on faster flows, leading the hydrodynamic stress to depend
quadratically on the droplet diameter. Equating that hydrodynamic stress with a constant,
maximal interfacial tension at snap-off trivially yields the desired scaling exponent.
To make such a force balance relation more precise, we begin by equating the
drag force Fd with the interfacial tension force Fγ at the moment of snap-off

Fd =

π
8

C d ρ CP v∞2 D 2 = Fγ = πD0 γ ,

(4.1)

where v∞ is the far-field velocity at droplet midline and Cd = Cd(Rep,λ) is the drag
coefficient for a spherical droplet with particle Reynolds number Rep = ρCPv∞D/μCP and
viscosity ratio λ = μDP/μCP. Eq. (4.1) can be rearranged as
2
v ∞2 D 2
ρ CP
8 ρ CP D0 γ
8
−2
= Rep2 =
=
OhCP ,
2
2
C d μ CP
Cd
μ CP

(4.2)

where we have introduced the CP Ohnesorge number, OhCP = μCP/(ρCPD0γ)1/2, which is a
ratio of viscous and capillary time scales. Solving Eq. (4.2) for the droplet diameter is not
trivial since Rep and Cd depend on D. Careful examination of Eq. (4.2) reveals that Rep at
snap-off is independent of Ca, and a function only of material properties and the pore
size. Substituting the approximation v∞ = (D/2)(dv/dz) and rearranging dimensionless
groups yields:
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{

D / D0 = (32 / C d ) OhCP
1/ 4

1/ 2

}Ca

−1 / 2

= kCa −1 / 2 ,

(4.3)

where we have introduced k for the prefactor in braces. The parameter k is nearly
independent of Ca, and depends almost entirely on CP properties, with the only DP
contribution coming from the viscosity ratio λ. Because of the small exponents on Cd and
OhCP, k varies little over a wide variety of fluid-fluid systems. This corresponds to the

earlier mentioned square root scaling with shear rate, as Ca ∝ dv/dz.
For creeping flows, Rep < 1, Eq. (4.3) can be solved by substituting the Hadamard
and Rybczynski relation13, Cd = [8(3λ+2)/(1+ λ)]Rep-1, which was derived for liquid
spheres in a shear flow (in the absence of a wall), canceling OhCP
⎛ D
⎜⎜
⎝ D0

⎞ ⎛ 2λ + 2 ⎞
⎟⎟ = ⎜
⎟
⎠ ⎝ 3λ + 2 ⎠

1/ 2

Ca −1 / 2 .

(4.4)

Thus, for small pores and slow flows, we can derive an exact force balance expression for
D/D0. The Rep in our experiments, however, ranges from 2 < Rep < 150, so we solve Eq.

(4.3) iteratively using an expression for Cd given by Saboni and Alexandrova13
appropriate for our intermediate Rep case, which amounts to a 35% correction in the drop
diameter for the highest Rep. Moreover, we compute the shear rate from our measured
volumetric flow rate, QCP, using an analytical solution by White14, to derive the
expression dv/dz = 9.7QCP/H1.67W1.33.
Figure 4.2(b) shows the Ca dependent droplet size data, rescaled as (1/k)D/D0. If
our force balance were exact, the data would fall along the line (1/k)D/D0 = Ca-1/2. This
procedure does collapse the droplet size data, with a residual spread in normalized drop
sizes of about 10% across all the fluid systems studied. The collapsed data, however, fall
74

systematically below the expected curve by about 20%. To investigate this discrepancy,
we simulated the XME process using computational fluid dynamics15-16. The simulation
results, also plotted in Figure 4.2(b) with the symbol ( ), show excellent agreement with
the experimental findings. Thus, the discrepancy is presumed due to the simplifying
assumptions made in the force balance, e.g. neglecting the hydrodynamic effect of the
membrane17, assuming that the drag force acts perfectly antiparallel to the interfacial
tension force, or neglecting neck effects similar to those in the dripping faucet18. To
predict the XME droplet size a priori, one should use a value about 80% of that predicted
by Eq. (4.3).

Figure 4.2 – (a) Droplet diameter D versus shear rate dv/dz for all
fluid systems, and (b) Collapse of scaled droplet size (1/k)D/D0 as a
function of Ca, with k calculated from Eq. (4.3). The collapsed
experimental data fall roughly 20% lower than the force-balance
prediction (solid line), comparable to results from computational fluid
dynamics ( ). See Table 4.1 for symbol definitions.
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4.5 Modeling of the dripping-jetting transition
Next we construct phase diagrams that delimit where dripping and jetting occur as
a function of We and Ca, shown in Figure 4.4(a,c). We define jetting as occurring when
the length of the neck, Ln, at snap-off exceeds the droplet diameter: Ln/D > 1, which
correlates with large changes in D/D0 over the range of Ca studied, cf. Figure 4.3. A
similar criterion is used in the dripping faucet literature19. At sufficiently low We and Ca,
dripping is always observed, and as either is increased, the behavior will eventually
transition to jetting. Qualitatively, these phase diagrams exhibit the same form as those
for coaxial liquid streams5 and dripping faucets20, at least when Ca is substituted for the
Bond number Bo in the latter case.11 In retrospect, one could have anticipated that jetting
will occur whenever the force causing surface extension exceeds that causing surface
contraction. This will happen independent of whether that force comes from the kinetic
energy of the DP, the drag from the flowing CP, or from gravity. The transition, however,
does not occur at the same location in Ca-We space for all fluid systems, rather, it is also
controlled by the DP Ohnesorge number, OhDP = μDP/(ρDPD0γ)1/2. Figure 4.4(b) shows
how the transition varies in We-OhDP space at low Ca, and again we find remarkable
similarity to what has been observed in the dripping faucet geometry19.
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Figure 4.3 – (a) Increase in neck length Ln relative to droplet
diameter D as We is increased, and (b) corresponding decrease in
droplet diameter ratio D/D0 as the dripping-jetting transition Ln/D
= 1 is exceeded. Neck length Ln always grows near the transition, and
D/D0 subsequently varies (but does not always decrease) from the
stable size observed in the dripping regime. See Table 4.1 for symbol
definitions.

In the dripping faucet, the separatrix between dripping and jetting has been
determined. Clanet and Lasheras derived an analytical expression20 to describe the
dripping-jetting transition in We-Bo space when OhDP → 0. For finite OhDP, their
expression quantitatively describes our low and high OhDP data when their We and Bo are
replaced by a rescaled We and Ca, respectively, as shown by the solid lines in Figure
4.4(a) and Figure 4.4(c). Similarly, Ambravaneswaran et al. generated a phase diagram in
We-OhDP space at fixed Bo through numerical simulations19; their data are reasonably

well described by a two-segment piecewise power-law in OhDP (corresponding to the
inviscid and finite μDP limits). Again, this expression describes our data when OhDP is
rescaled; the solid line in Figure 4.4(b) shows this result. We find that the product of
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these two functions (with rescaled Ca and OhDP) describes our dripping-jetting transition
surface in Ca-OhDP-We space:
−α

{

[

]

We = (c1OhDP ) 1 + c 2 Ca 2 − (1 + c 2 Ca 2 ) 2 − 1

1/ 2

},

(4.5)

where c2 = 860, and c1 = 0.10 and α = 0.89 for OhDP ≥ 0.03, or c1 = 2.27 = (0.10)(0.03)0.89

and α = 0 for OhDP < 0.03, as determined by least squares minimization. This surface

is plotted in Figure 4.4(d).

Figure 4.4 – Dripping to jetting phase behavior as a function of We,
Ca and OhDP. Dripping is indicated by open symbols, jetting by filled
symbols. In (a) and (c), which plot the same region of Ca-We space at
different OhDP, jetting is always seen at sufficiently high values of
either We or Ca. The transition curve, shown by the solid lines, is a
function of OhDP and moves downward as OhDP is increased. In (b),
viewing the data in OhDP-We space highlights the OhDP dependence (at
low Ca). In (d), the surface separating dripping and jetting regimes,
based on Eq. (4.5), is adapted from the references.19-20. Jetting can also
be observed below this surface if the predicted droplet size is D/D0<2,
not shown. See Table 4.1 for symbol definitions.

78

We also observe another dripping to jetting transition mechanism. Even at small
Ca and We, under conditions where Eq. (4.3) predicts droplet sizes below the Rayleigh

limit D/D0 ≈ 2, dripping gives way to a jet running tangent to the membrane, without
apparently wetting it. In this case, the jet breaks up downstream to yield droplets of size
D/D0 ≈ 2. This condition resembles operating conditions that prevail during

emulsification in T-junctions7. Taken with the preceding result, the (Ca, OhDP, We) triple
appears sufficient to determine whether dripping or jetting will occur during any XME
process.

4.6 Summary
Dripping, jetting and the transition between them show remarkably similar
characteristics in radically different geometries. Indeed, we were even able to adapt and
analytically extend functional forms derived for the transition in faucets to the XME
geometry with simple rescaling of the groups. Less surprising, the geometric details
influence the relationship between droplet size and the relevant dimensionless groups. In
the cross-flow membrane geometry as in the others, a force balance suffices for a precise
prediction of droplet size as a function of process conditions. It seems likely that such
relationships prevail in other microfluidic geometries as well. It remains unknown to
what extent the lack of axisymmetry in our geometry affects the hydrodynamic
singularity at the moment of snap-off21, or how the process is modified by nonNewtonian fluid behaviors such as extensional elasticity22.
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Chapter 5: Producing Monodisperse Drug-Loaded
Polymer Microspheres via Cross-Flow Membrane
Emulsification: The Effects of Polymers and Surfactants
Cross-flow membrane emulsification (XME) is a method for producing highly
uniform droplets by forcing a fluid through a small orifice into a transverse flow of a
second, immiscible fluid.

We investigate the feasibility of using XME to produce

monodisperse solid microspheres made of a hydrolysable polymer and a hydrophobic
drug, a model system for depot drug delivery applications. This entails the emulsification
of a drug and polymer-loaded volatile solvent into water followed by evaporation of the
solvent. We use a unique side-view visualization technique to observe the details of
emulsion droplet production, providing direct information regarding droplet size,
dripping frequency, wetting of the membrane surface by the two phases, neck thinning
during droplet break off, and droplet deformation before and after break off. To probe the
effects that dissolved polymers, surfactants, and dynamic interfacial tension may have on
droplet production, we compare our results to a polymer and surfactant-free fluid system
with closely matched physical properties. Comparing the two systems, we find little
difference in the variation of particle size as a function of continuous phase flow rate. In
contrast, at low dripping frequencies, dynamic interfacial tension causes the particle size
to vary significantly with drip frequency, which is not seen in simple fluids. No effects
due to shear thinning or fluid elasticity are detected. Overall, we find no significant
impediments to the application of XME to forming highly uniform drug-loaded
microspheres.
Appeared in Langmuir, by Robert F. Meyer, W. Benjamin Rogers, Mark T. McClendon and John C.
Crocker, Vol. 26, Issue 18, pp. 14479-14487. © 2010 by American Chemical Society.
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5.1 Introduction
Emulsion-based materials have a diverse set of applications across many fields
including electronics, cosmetics, foods, and pharmaceuticals1. In controlled release drug
delivery applications, it has been shown that particles generated from monodisperse
emulsions have well defined drug release rates, and thus particle size can be used to
engineer improved formulations that deliver drug in a predetermined manner2-3. Methods
for producing monodisperse emulsions have been a popular topic of investigation in
recent years, employing techniques such as flow focusing4, shear rupturing5, acoustic
excitation6, microfluidic T-junction emulsification7, and membrane emulsification8.
Membrane emulsification describes a wide variety of techniques whereby a dispersed
phase (DP) is forced through an orifice in a membrane into an immiscible continuous
phase (CP), thereby generating an emulsion. To date, researchers have investigated the
impact of the type of membrane and pore used, the method for detaching emulsion
droplets, and the geometry in which the droplets are formed1, 9-10.
We focus on cross-flow membrane emulsification (XME), due to the wide
adjustability of particle size and the potential for high production rates through the use of
multiple orifices in one device. In XME, nascent droplets are formed at the membrane
pore while subjected to a transverse shear flow, as shown in Figure 5.1(a). The drag
force exerted by the CP increases as the drop grows larger, until such point that the
interfacial tension force can no longer hold onto the drop, and the process begins anew.
It is this balance of drag and interfacial tension forces which allows for precise control
over the size of the droplets which are produced, as we showed recently in simple
fluids11.
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Figure 5.1 – (a) Schematic of the XME process and the important
parameters, and (b) scale rendering of the CP fluid channel,
membrane and optical path. All components are contained within a
machined aluminum carrier which is not shown.

For many practical applications, including the production of drug-loaded
microspheres12, emulsions must contain polymers,

surfactants, and other substances

which introduce non-idealities into the system's fluid mechanics.

In this work, we

examine the feasibility of using XME to generate such drug-loaded particles.
Specifically, we investigate whether non-Newtonian viscosity, elasticity, and dynamic
interfacial tension modify the XME process in an observable way, largely by comparing
the drug and polymer-loaded system to a simple fluid system with similar physical
properties. Next, we investigate operational aspects related to the production of particles,
including the uniformity of particles produced. Finally, we explore droplet deformation
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and rupture which can occur after particle generation but prior to drying, and result in
size distributions of lower uniformity.

5.2 Background
Because membrane emulsification has received significant attention in
recent years, considerable background can be found in recent review papers1,

9-10, 12

.

XME in particular was studied experimentally by Peng and Williams13, and numerically
by Abrahamse, et al.14 The effect of dynamic interfacial tension on XME was studied by
van der Graaf, et al.15, but their study did not show a clear relationship between droplet
production rate, the interfacial tension at that rate, and the resultant droplet size. Using a
T-shaped microchannel geometry, Husny and Cooper-White16 demonstrated the
substantial consequences fluid elasticity has on droplet production, including long-lived
droplet necks and abundant satellite droplets. However, this study used a DP of water
with dilute concentrations of high molecular weight poly(ethylene oxide), which is well
known to exhibit elastic effects, and was not oriented towards manufacturing solid
particles. Preparation of PLG particles using stirred cell membrane emulsification was
performed by Gasparini et al.17, and this study investigated many aspects of the process,
including formulation variables and the drying procedure, but the study generated fairly
polydisperse particles and did not investigate the physics of the emulsification process
itself.
In our earlier study in pure fluids11, we found two distinct processing regimes:
dripping and jetting. When the DP volumetric flow rate, QDP, is sufficiently low, the
system will drip, and droplets of constant size are formed and detach near the membrane
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pore. The final droplet diameter, D, decreases in relation to the magnitude of the shear
stress, which is proportional to the CP viscosity, μCP, and the CP shear rate, dv/dz.
Conversely, D increases in relation to the interfacial tension, γ, and the pore diameter, D0.
This leads us to introduce the capillary number Ca, which is a ratio of these drag and
interfacial forces: Ca = μCP(dv/dz)D0/γ. These are the only two significant forces present
as long as buoyancy is negligible, which is the case for the small droplets studied here.
At higher QDP, the inertia of the DP can no longer be neglected. A jet forms, and the jet
breaks into rather polysdisperse droplets far from the membrane pore due to the Rayleigh
instability18. The system gets closer to jetting with increasing inertial force of the DP,

ρDPQDP2/D02, where ρDP is the DP mass density.

However, the tendency to jet is

decreased by the interfacial tension force, γD0. Thus we are interested also in the ratio of
these forces, which is the Weber number, We = ρDPQDP2/D03γ.
For a system consisting of pure fluids, we can use dimensional analysis19 to
determine the dimensionless groups other than Ca and We which might be useful for
study. In XME there are 5 physical properties, 2 flow rates, and 2 length scales that are
relevant. Since these contain the dimensions of length, mass and time, there should be at
most 9 – 3 = 6 independent dimensionless groups. It is intuitive that the droplet diameter
ratio D/D0 is a function of We and Ca, but dimensional analysis indicates that there are
three additional dimensionless groups present. These can be chosen as a viscosity ratio λ
= μDP/μCP, and two Ohnesorge numbers, OhCP and OhDP, where Oh = μ/(ρD0γ)1/2. The
Ohnesorge numbers for each phase are a ratio of viscous and capillary time scales within
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that phase. Thus it is expected that D/D0 = f(Ca, We, OhDP, OhCP, λ). In practice, it has
been shown that for systems of low to moderate OhDP operating at low We11:
D
= k0Ca−1/ 2
D0

(5.1)

where k0 is a function of physical properties and length scales alone, and can be treated as
a constant within a given experiment. The value of k0 can be calculated according to
⎛ 32 ⎞
⎟⎟
k 0 = ⎜⎜
C
⎝ d⎠

1/ 4

Oh CP

1/ 2

.

(5.2)

In the preceding expression, Cd is the drag coefficient for the droplet in the cross-flowing
CP, and can be estimated from empirical correlations20 which relate to the Reynolds
number Re = ρvCPD/μ, and the viscosity ratio λ:
⎡ ⎛ 24
4 ⎞ 14.9 ⎤ 2
3λ + 2
⎢λ ⎜ Re + Re1 / 3 ⎟ + Re 0.78 ⎥ Re + 40 Re + 15λ + 10
⎝
⎠
⎦
.
Cd = ⎣
(1 + λ ) 5 + Re 2

(

)

(5.3)

This expression, derived for fluid spheres in an external flow (in the absence of a wall) is
accurate for 0.01 < Re < 400 and any viscosity ratio. It should be noted that Re is not an
independent dimensionless group, and can be expressed in terms of the other groups
previously discussed, Re = CaOhCP-2(D/D0)2.

5.3 Methods
5.3.1 Experimental Apparatus
Figure 5.1(a) shows a schematic of the XME process, and Figure 5.1(b) shows an
isometric drawing of the interior of the apparatus used in these experiments.
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The

membrane holder is constructed from aluminum stock, and consists of a top and bottom
half, between which the membrane is sandwiched. CP is pushed from a pressurized tank
through a flowmeter (FMTE4, DEA Engineering, Anza, CA) and into the membrane
holder from the bottom. DP is pumped into the bottom of the membrane holder using a
syringe pump (Model 11 Plus, Harvard Apparatus, Harvard MA). The pressures of both
CP and DP are measured via pressure transducers (SPT4V, Invensys, Milpitas, CA).
After changing direction, the CP flows along the membrane surface down a long
rectangular channel 6.4mm wide by 3.2mm high. In some experiments, a solid insert is
placed in the channel to decrease the height to 1.0mm. In the center of the channel, DP
passes through the membrane and into the cross-flowing CP, generating a droplet. The
emulsion then travels down the remainder of the channel, and exits the membrane holder
at the bottom, and finally proceeds to the collection vessel.

5.3.2 Membranes
Disk-shaped membranes are constructed of stainless steel and cut to 50mm in
diameter from 0.30mm thick sheet stock. For each membrane, a single pore is cut into
the center of the membrane using one of three methods: laser drilling (Oxford Lasers,
Shirley, MA), mechanical drilling (Roland Research Devices, Trenton, NJ), or electrical
discharge machining (EDM) (Makino / Hummingbird Precision Machine Co., Lacey,
WA).

Electron micrographs showing the pores made via the various methods are

provided in Figure 5.2.

For the majority of the studies, the mechanically drilled

membrane shown in Figure 5.2(c) is used, because of the membrane's favorable wetting
properties. Wetting of the membrane by the DP, readily visualized in our apparatus, can
lead to a larger effective orifice size, and correspondingly anomalous droplet sizes. The
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EDM membrane in Figure 5.2(b) is used for the mass-produced particles shown in Figure
12, while the laser drilled membrane in Figure 5.2(a) is not used in the present work, but
is shown for comparison purposes.

Figure 5.2 – Membranes manufactured via different methods.
Parts (a), (b) and (c) show stainless steel membranes of varying pore
diameters, manufactured using laser drilling, electrical discharge
machining (EDM), and mechanical drilling, respectively.

5.3.3 Video Microscopy
During production of the emulsion droplets, the process is observed from the side
of the channel, through the use of two 1/8" right-angle prisms (Thorlabs, Newton, NJ)
flush mounted in the channel wall. Light is directed from above into the first prism,
where it is then reflected through the droplet-forming region and into the second prism.
The second prism subsequently reflects the light up through a long working distance
video microscope and into a CCD camera (COHU 4915, San Diego, CA) collecting 30
interlaced frames per second at 640 x 480 resolution. Video images are collected using
Video Toolbox (version 1.65, Zarbeco, Randolph, NJ), processed using VirtualDub
(version 1.6.19, virtualdub.org), and analyzed using ImageJ (version 1.38x,
rsb.info.nih.gov) and Matlab (R2007a, The Mathworks, Natick, MA).
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Figure 5.3 – Example images of PLG droplets. The side view set up
allows for observation of phenomena not observable from above, such
as wetting of the membrane surface, thinning of the droplet neck during
break-off, and droplet deformation due to the shear flow.

5.3.4 Materials
When generating drug loaded polymer microspheres, the DP consists of the
solvent dichloromethane (DCM), the biodegradable polymer poly(D,L-lactide-coglycolide) (PLG), and haloperidol as a model drug. DCM was obtained from Fisher
Scientific (Fairlawn, NJ). PLG (50:50 D,L-lactide:glycolide, ester terminated, inherent
viscosity = 0.82dL/g in HFIP) was obtained from Birmingham Polymers (Pelham, AL).
Haloperidol was obtained from Sigma (St. Louis, MO). The CP consists of the surfactant
poly(vinyl alcohol) (PVA) dissolved in deionized (DI) water.

PVA (22kDa, 88%

hydrolyzed) was obtained from Acros Organics (New Jersey, USA).

DI water (18

MΩ/cm, Easypure Barnstead) was used throughout this study. For comparison to ideal
fluids, 1-decanol (Acros Organics) acts as the DP, and the CP consists of DI water.
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Table 5.1 – Formulations of decanol and polymer-loaded systems.

System

CP

DP

Decanol

DI water

Polymer

99% DI water
1% PVA

decanol
90% DCM
9% PLG
1% haloperidol

5.3.5 Preparation of CP and DP
For the production of polymer microspheres, CP is prepared by dissolving PVA in
warm DI water at a concentration of 1% by weight. After dissolution of the PVA, the
solution is filtered through a 14µm cellulose acetate filter and allowed to cool to room
temperature. DP is prepared by mixing haloperidol, PLG and DCM in a closed container
overnight. In most experiments, the DP contained 9% PLG and 1% haloperidol on a
weight basis, and in one experiment, the concentrations were raised to 11% PLG and
1.2% haloperidol so that droplets could be collected and dried without affecting the
particle size distribution.

5.3.6 Microsphere Drying
The classical oil-in-water emulsion-solvent evaporation method is used in
preparation of the microspheres21-22. In brief, after production of the emulsion droplets
via XME, DCM is extracted into the CP, where it is sparingly soluble. The DCM is then
readily evaporated from the collection vessel due to its low boiling point, yielding solid
drug-loaded polymer microspheres.

5.3.7 Sizing of Microspheres
In most experiments, the droplets produced via XME are deformed from a sphere
and into a prolate spheroid due to the shear stress imposed by the flowing CP. This
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complicates slightly the measurement of particle size. The diameter of a droplet is
measured in two ways.

In the simplified method, the major and minor diameters are

measured manually from a video frame containing the droplet image. When higher
resolution and/or larger sample sizes are needed, an automated image analysis routine
processes the images such that an ellipse can be fit to the droplet perimeter. In both
cases, the reported diameter is then calculated as the average of the major and minor
diameters. While an assumption that the particle takes the shape of a prolate spheroid
with equivalent spherical diameter D = (Dminor2Dmajor)1/3 may be more appropriate for
highly deformed particles, for the small deformations seen here the result is
indistinguishable from this and other advanced diameter calculation techniques.

5.3.8 Physical Properties
Fluid physical properties are calculated in the following ways. Densities are
calculated by weighing a known volume of fluid. Viscosity is measured by capillary
viscometry in an Ubbelohde viscometer. Interfacial tension is measured via the drop
weight method, which was analyzed in detail by Yildirim, Xu and Basaran23. In this
technique, the interfacial tension between the two phases is inferred by measurement of
the weight of a drop that falls from a needle tip, and applying an empirical correlation.
By varying the rate of droplet production, we are able to measure the interfacial tension at
the moment of drop snap-off, as a function of the drop period. This dynamic interfacial
tension is a complex phenomenon, and has been well described in a recent review paper
by Eastoe and Dalton24. The physical properties of the various DPs are provided in Table
5.2.
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Table 5.2 – Physical properties of decanol and polymer-loaded systems.

T=18°C
System
Decanol
Polymer

DP Properties
CP Properties
CP/DP
Calculated
ρ
μ
ρ
μ
γ
(kg/m3) (mPa-s) (kg/m3) (mPa-s) (mN/m) OhCP OhDP λ
824

13.6

998

0.98

9.5

0.034

0.514

13.9

1327

14.9

998

1.41

8.0*

0.053*

0.483*

10.6

23

*evaluated at a drop period of Δt = 1s using the drop weight method

5.3.9 Calculation and Measurement of Channel Shear Rate
To relate the measured CP volumetric flow rate QCP to the shear rate dv/dz in the
center of the channel and at the membrane surface, we utilize an empirical expression
proposed by Purday25
6Q
⎛ dv ⎞
= 2CP
⎜ ⎟
⎝ dz ⎠ pore H W

⎛ m +1⎞
⎜
⎟
⎝ m ⎠

(5.4)

where H is the channel height, W is the channel width, and m is an empirical factor
defined by m = 1.54W/H when H/W < 2/3. This expression is far less cumbersome than
the full analytical solution for laminar flow in a rectangular channel, and has minimal
error across the range of conditions studied here.
To confirm the predictions of Eq. (5.4), titania coated glass microspheres
(Isospheres-T, Microsphere Technology, Edinburgh, UK) are used to observe the CP
flow dynamics in situ. The microspheres are observable as a dark spot on a bright
background, but only when they are within the focal plane of the microscope. Because
we are interested in the velocity at the center of the channel, and the channel is wide with
respect to its height, variations in the depth of observed microspheres are unimportant.
By analyzing the movement of individual microspheres across adjacent video frames, the
velocity of the microspheres and thus the carrier fluid can be calculated.
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5.4 Results and Discussion
We are primarily concerned with the size of the particles that are produced, and
the rate of their production, and these factors can be controlled by two parameters within
a given experiment: QCP and QDP. These flow rates are directly proportional to the more
intuitive parameters of shear rate, dv/dz, and DP velocity, vDP = 4QDP/πD02. Looking first
at the size of droplets produced as a function of the shear rate, we find there is great
similarity when comparing the PLG and decanol systems, see Figure 5.4.

This is

surprising given the complexity of the PLG system relative to the decanol system. Both
show the expected trend of rapidly decreasing particle size with the initial increase in
shear rate, followed by more gradual decreases as the shear rate is increased further. This
will be shown later to be consistent with the model presented in Eq. (5.1), which states
that D ∝ (dv/dz)-1/2.

Figure 5.4 – Drop diameter D as a function of CP shear rate dv/dz
for the PLG (filled circles) and decanol (open circles) systems. For
both systems, D0 = 90µm, and the flow rates were similar at QDP =
0.7mL/hr and QDP = 1.0mL/hr for the PLG and decanol systems,
respectively.
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In Figure 5.5, we examine the size of droplets produced as a function of QDP,
while dv/dz is held constant. In general, a small increase in D is expected as QDP is
increased, as has been seen in both XME26-27 and in other geometries23. Indeed, this trend
is observed, and as can be seen, there is a significant difference in the functional
relationship between the decanol and PLG systems. The decanol system shows a gradual
linear increase in D as QDP is increased, with a slope of about 20µm/(mL/hr). The PLG
system shows a similar increase in D at high flow rates, but shows a drastic change in D
at low flow rates. These two trends are consistently seen independent of the value of
dv/dz. It appears that the primary difference between the decanol and PLG systems is this
dependence of particle size on production rate.

Figure 5.5 – Drop diameter D as a function of DP flow rate QDP or
velocity vDP for the PLG (filled circles) and decanol (open circles)
systems. For both systems, D0 = 90µm, and the CP shear rates were
similar at dv/dz = 1210s-1 and dv/dz = 970s-1 for the PLG and decanol
systems, respectively.

Since in a production setting, the DP flow rate determines the rate of particle
production, it is desirable to modify the size model given in Eq. (5.1) in such a way that
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the model is predictive of particle size as a function of both dv/dz and QDP. It is clear
from Figure 5.5 that for decanol, at constant dv/dz, D = mQDP + b, where m and b are
constants for a given shear rate.

In non-dimensional form, the relationship can be

generalized to
D
= (k0 + k1We1 / 2 )Ca −1 / 2
D0

(5.5)

where k1 is a constant for a given experiment with set dv/dz, and is expected to be a
function of OhDP. This relationship is consistent with what has been observed in the
dripping faucet23, a geometry quite similar to that encountered in XME. Of course this
model is phenomenological in nature, and does little to help elucidate the cause of the
phenomena we observe. Yet it will prove useful in analyzing the differences seen
between our simple decanol and complex polymer systems.
While it seems natural when comparing these systems to utilize the dimensionless
variables introduced earlier; such an approach is complicated by the complexities of the
PLG system. In particular, shear thinning of the CP, viscoelasticity of the DP, and
dynamic interfacial tension can all cause the physical properties of the system to become
functions of the process conditions, leading them to be coupled in non-trivial ways. Thus
before non-dimensionalizing the systems under study, we check the requisite physical
properties for non-ideal behavior.
PVA is a common polymeric surfactant for manufacturing PLG microspheres,
due to its ability to lower interfacial tension and stabilize emulsion droplets against
coalescence21-22. Relative to pure water, it also raises the viscosity of the CP by about
40% at a concentration of 1% by weight. This then increases the shear stress at a given
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shear rate. But for polymer solutions, viscosity is often a function of shear rate, and
typically decreases with increasing shear. If this were the case, it would negate the
assumed velocity profile and subsequent calculations. Because of our ability to observe
the region of droplet formation from the side, we use particle velocimetry to observe the
velocity profile in situ25. Typical results are provided in Figure 5.6. For all cases studied,
the experimentally measured vCP and dv/dz match the theoretical predictions from Eq.
(5.4) to within experimental error, and thus we conclude that an assumption of constant
viscosity in the CP is appropriate.

Figure 5.6 – Distance from membrane surface as a function of
continuous phase velocity vCP for the PLG system with a CP
containing 1% PVA.

Solid points are experimentally measured

velocities, the solid line is the theoretical prediction, and the dashed
line is the slope at the wall based on a parabolic least-squares fit to the
entire data set.

Having examined the CP and finding no effects of the dissolved polymer, we now
investigate the DP, where the polymer is present at much higher concentration and has
higher molecular weight.

There are two possible effects that could influence the

dynamics of our system. As before, we would not be surprised to find that the viscosity
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is shear thinning. However, once the DP passes through the membrane and into the CP,
it experiences only a moderate shear rate due to its high viscosity and stress continuity at
the DP/CP interface. In addition, DP shear viscosity only plays a minor role in the size
model presented here, Eqs. (5.1) and (5.3). Thus it is not expected that shear thinning in
the DP will cause any deleterious behavior during XME. It is also possible that elastic
effects such as non-linear elongational viscosity could be observed, which result in longlived droplet necks, and thus droplets that detach far from the membrane pore along with
numerous satellite drops16. To test for this second possibility, we measure the diameter
of a droplet neck, from the first instant of droplet formation up until the critical time of
neck breakage, tc. If no elastic effects are present, the neck diameter should decrease in
size according to Dn ~ (tc - t)2/3. Figure 5.7 shows the results, which are generated by
imaging the process stroboscopically. That is, by adjusting the dripping frequency to
near a multiple of the frame rate we can access sub-millisecond dynamics with a
conventional video camera. In general, we see only slight differences between the
decanol and PLG systems, and both systems display the expected scaling of Dn with t at
times near the critical point. Furthermore, we do not witness the long lived droplet necks
seen elsewhere, thereby indicating the lack of significant elastic effects16, 28.
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Figure 5.7 – Droplet neck diameter Dn as a function of time t for
the PLG (filled circles) and decanol (open circles) systems. The
difference in breakup time is due to slightly different production rates.
The inset shows the same data plotted as Dn vs. (tc – t) on logarithmic
coordinates, where tc is the critical time of neck breakage; the dashed
line demonstrates the theoretically predicted slope of 2/3.

Although not observed in the current system, in general, nonlinear elongational
elasticity is expected to arise if the relaxation time of the polymer exceeds the
characteristic flow time within the droplet neck, i.e. the Deborah number De = λε& > 1,
where λ is the longest polymer relaxation time and ε& is the highest strain rate of the flow
field. With the data collected in this study, we can calculate ε& and λ as follows. The
strain rate ε& as the droplet nears snap off can be estimated28 as ε& = −
results in ε& = 2400s −1 for the data presented in Figure 5.7.

2 dDn
, which
Dn dt

The relaxation time λ in

dilute solutions can be estimated from Zimm theory29

λ=

6[η ]η s M w
π 2 RT
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(5.6)

where [η] is the intrinsic viscosity of the polymer solution, ηs is the solvent viscosity, Mw
is the polymer molecular weight, R is the gas constant and T the temperature. Even
though the polymer concentrations used herein are far from dilute, we can use Eq. (5.6) to
gain a rough idea of how close we are to the onset of elastic effects30. Using ηs = μDP =
14.9mPa-s, [η] = 57mL/g and Mw = 137 000g/mol, we calculate λ = 3 x 10-5s. Thus De =
0.07, significantly below the transition region. Even though the solution viscosity is
high, and this retards polymer relaxation, the molecular weight is low enough that the
chains can fully recoil when strained, and hence elastic effects are not seen. An analysis
of the relationship μDP = μDP(xPLG) (data not shown) reveals that a doubling of the DP
polymer fraction, to xPLG = 18%, would result in De ≈ 1. Similarly, a doubling of the
polymer molecular weight to Mw = 270 000g/mol would also result in De ≈ 1. For typical
manufacturing of drug loaded polymer microspheres, these points represent extreme
operating conditions, yet there are certainly other applications where high polymer
concentration and/or Mw could lead to elastic effects being observed.
Moving now to an analysis of the effects of dynamics interfacial tension, in
essence, we expect the interfacial tension at the moment of snap-off to differ significantly
from its long-time value. One conventional approach for characterizing the dynamic
interfacial tension is the drop weight method23. We performed such measurements,
despite expecting the conditions during XME to differ somewhat from the dynamics of
gravity driven drop break off from a needle tip. To probe different time scales for droplet
production, we use a variety of needle diameters and volumetric flow rates, all while
maintaining the droplet production in the dripping regime. The results are shown in
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Figure 5.8. As can be seen, the interfacial tension of the decanol system does not change
significantly across the range of droplet frequencies studied, with a relative standard
deviation of 6%. But the PLG system shows a large effect, dropping from about γ =
11mN/m at Δt = 0.5s to γ = 3mN/m at Δt = 30s. For typical XME experiments conducted
here, the time scale for droplet production Δt = πD3/6QDP ranges from Δt ≈ 0.01s to Δt ≈
1s.

Due to the dripping-jetting transition, we are unable to directly measure the

interfacial tension at time scales less than Δt ≈ 0.5s, and thus we turn to modeling to
predict what may occur at shorter times.

The phenomenological Rosen equation24

predicts that at times infinitesimally close to zero, the interface will behave as if there is
no surfactant adsorbed, and at very long times, surfactant will completely cover the
interface, and the interfacial tension will plateau. In between, a power law dependence is
predicted:

γ 0 − γ (t ) ⎛ t ⎞
=⎜ ⎟
γ (t ) − γ ∞ ⎝ τ ⎠

−n

(5.7)

where γ0 and γ∞ are the interfacial tensions at time zero and infinity, and τ and n are
fitting constants. We find γ0 by measuring the interfacial tension when no surfactant is
present, and γ∞ by forming droplets over time periods greater than 500s.

Using these

initial and terminal values, and then adjusting τ and n to fit the intermediate data, we find
that the Rosen equation fits our drop weight method data well over the time period
observed, with the average error being about 5%.
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Figure 5.8 – Interfacial tension γ as a function of drop period Δt for
the PLG (filled circles) and decanol (open circles) systems, as
measured using the drop weight method23. The dotted line shows the
average value of γ for the decanol system, and the solid line is a fit of
the PLG data to Eq. (5.7).

Summarizing the non-ideal effects investigated thus far, we have seen that shear
thinning viscosity and fluid elasticity do not play a role in the dynamics of XME under
the conditions studied here. Interfacial tension, however, seems to change significantly
over large time scales, and thus could be responsible for the differences seen in droplet
size vs. production rate for the decanol and PLG systems. Using the insight provided by
the Rosen equation, we could directly substitute Eq. (5.7) into Eq. (5.5) to see if the
results of Figure 5.5 can be predicted. However, when γ is not constant, both Ca and We
are affected simultaneously. Thus it is more instructive to use Eq. (5.5) to directly
compute γ using the measured flow rates and droplet diameters, as a function of the XME
dripping period, shown in Figure 5.9. As expected, the results for the simple decanol
system show no sign of dynamic interfacial tension, and yield an average value,
9.63mN/m, consistent with what was measured via the drop weight method, 9.47mN/m.
The scatter in the data is a consequence of the fact that γ ~ D3, implied by Eq. (5.1), (5.2)
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and (5.3), making the computed tension very sensitive to small errors in the measurement
of droplet diameter.

Figure 5.9 – Interfacial tension γ as a function of drop period Δt for
the PLG (filled circles) and decanol (open circles) systems as
calculated from Eq. (5.5) during XME. The dotted line shows the
average value of γ for the decanol system, and the solid line is a fit of
the PLG data to the Rosen equation.

The PLG data do show the expected trend of decreasing interfacial tension with
increasing droplet period, and the measured values are within the range observed
previously, however the values are significantly lower than what is predicted by Eq. (5.7)
at comparable dripping frequencies in both processes. We again use the Rosen equation
to fit the γ –Δt curve, and assume the same initial and terminal values γ0 and γ∞, with fit
parameters shown in Table 5.3. The time constant τ, which moves the curve horizontally,
is an order of magnitude smaller for the XME data. This is not surprising given that
during XME, convection drives surfactant to the droplet interface, an effect not seen in
the drop weight method.

Thus the droplet interface achieves a given surfactant

concentration an order of magnitude faster during XME. The exponent n, which changes
the slope of the curve in log-log space, is about 1/3 of that measured via the drop weight
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method. A smaller slope is also predictable due to the strong convection present during
XME. When considering the strong convective forces, it could be considered surprising
that interfacial tension changes at all as a function of drop period. However, this result
could be explained by a slow surfactant adsorption process. Regardless, it seems that
dynamic interfacial tension can be held solely responsible for the subtle non-ideal
behavior we observe in the PLG system.
Table 5.3 – Rosen equation fit parameters.

Method
Drop weight
XME

γ0 (mN/m)

γ∞ (mN/m)

τ (s)

19.2
19.2

2.2
2.2

0.49
0.04

n
0.75
0.25

Although dynamic interfacial tension provides an adequate explanation for the
significant changes in D at low QDP seen in Figure 5.5, it is interesting to note that there
is no significant dynamic interfacial tension effect observed in Figure 5.4, where D is
plotted as a function of dv/dz. Thus we are tempted to simplify the problem, and test the
validity of Eq. (5.5) using a constant, average interfacial tension. This simplification is
further reinforced by the following fact. We saw before that when calculating γ from
measured values of D, errors are amplified because γ ~ D 3. However, when observing D
in an environment with changing γ, the dynamics are dampened because D ~ γ 1/3. Using
this methodology, we construct Figure 5.10, assuming for the PLG system γ = 9.6mN/m,
which is the average value in Figure 5.9 for drops produced across the same frequency
range. We find that the model does predict well the relationship between Ca and D/D0
for both the decanol and PLG systems. Yet we have argued that dynamic interfacial
tension is present in the XME system. We expect if dynamic interfacial tension is
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present, as Ca is increased, smaller drops will be made at a higher frequency. This
shorter time period between drops means that the interfacial tension at the time of snap
off will be higher, and thus the droplets will be slightly larger than otherwise expected.
Thus, when dynamic interfacial tension is present in XME, instead of D/D0 ~ Ca-0.5, the
exponent of Ca should be higher (closer to zero). Testing this quantitatively, a power law
fit to the PLG interfacial tension vs. time data presented in Figure 5.9 results in γ ~ Δt 0.11

. Using the fact that D ~ γ 1/3 and combining with Eq. (5.1), we find that the exponent

of Ca should be -0.5+0.11/3 = -0.46. Indeed, a power law fit to the PLG data presented
in Figure 5.10 reveals D/D0 ~ Ca-0.46. Consequently we conclude that an assumption of
constant interfacial tension results in minimal error when calculating Ca and using Eq.
(5.5), and the deviations from Eq. (5.5) can be readily determined if the relationship
between γ and Δt is known.
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Figure 5.10 – Scaled diameter ratio (1/k)D/D0 as a function of
capillary number Ca for the PLG (filled circles) and decanol (open
circles) systems. The solid line is a prediction based on Eq. (5.5),
(1/k)D/D0 = Ca-1/2.

In the end, our goal is to understand the effects processing parameters have on the
size of the particles produced, and the rate of their production, and use this information to
manufacture monodisperse polymer particles. Despite the sometimes non-ideal behavior
that is seen when polymers and surfactants are introduced to the system, particles can be
produced over a wide range of sizes and rates with a remarkable degree of precision. An
analysis using the automated sizing technique of n = 261 wet particles over a 10 min
period reveals a relative standard deviation (RSD) of 1.2%, while an independent analysis
of n = 81 close-packed, fully dry particles results in RSD = 1.6%. See Figure 5.11 and
Figure 5.12 for additional details. This small variability demonstrates that the ability to
manufacture uniform particles via XME is limited primarily by the operator's ability to
control those parameters that appear in the size model, namely the flow rates QDP and
QCP.
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Figure 5.11 – Diameter histograms for wet and dry drug loaded
PLG particles produced over a 10min time period, measured
independently via image analysis. The dry particles are shown in
Figure 5.12. The variables <D>, σ, and n refer to the mean, standard
deviation, and number of samples, respectively. We observe the ratio
of dry and wet particle diameters to be Ddry/Dwet = 0.488, which is close
to the expected value of Ddry/Dwet = (ρwet/ρdry xDP)1/3 = [(1)(0.122)]1/3 =
0.496 because the dry particles have no porosity and the polymer has
nearly identical density to the solvent.

Figure 5.12 – Fully dry drug loaded PLG particles produced over a
10min time period using the 60 μm membrane shown in Figure
5.2(b), at a shear rate of dv/dz = 2150 ± 110 s-1.

In some locations

two layers of particles can be seen. The mean diameter is 124μm with
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a standard deviation of 2 μm (n = 81). A histogram of the sizes is
shown in Figure 5.11.

From an operational viewpoint, it is important to understand the influence the
various model parameters have on the process.

First, the production rate per pore

calculated on a mass basis, i.e. the mass flow rate, dm/dt, is simply the product of the DP
solids fraction xDP with the total mass flow rate of the DP, dm/dt = xDPρDPQDP. Increases
in xDP make dm/dt rise proportionally, but make μDP, λ and OhDP increase much more
quickly, decreasing process robustness. In practice, solids loadings between 5% and 15%
are common. The flow rate QDP is the most logical parameter for raising dm/dt, but can
not be increased indefinitely. Changes to QDP modify We, the ratio of inertial forces to
interfacial forces. When We > 1, inertia dominates interfacial tension, and a jet is formed
from the membrane pore. Above this dripping-jetting transition, droplets break off far
from the membrane pore and are typically polydisperse11. Thus for normal operation,
production is optimal when QDP is chosen such that We ≈ 1, which occurs for QDP =
(γD03/ρDP)1/2. At this condition, the production rate per pore is dm/dt = xDP(ρDPD03γ)1/2.
For further increases in dm/dt, it makes sense to increase the number of pores until the
desired production rate is achieved. If each pore releases droplets into a common CP,
care must be taken in spacing the pores so that the presence of one droplet does not
interact with the growth and break off of nearby droplets. Because a force-free droplet in
a shear field only perturbs the flow field ~(D/r)-3, a single line of pores arranged
diagonally relative to the flow would only need to be spaced by a few droplet diameters
perpendicular to the flow to avoid perturbations from the single pore result. A useful
property of the XME system is that although variations in pore permeability might cause
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QDP to vary from pore to pore, in the dripping regime this effect does not lead to a

significant change in droplet diameter among pores.
Using the size models and physical and geometric parameters, we can predict the
range of particle sizes that are achievable using our XME system. On the large end,
particles can be manufactured up to the size restrictions set by the geometry of the
system. In order to make monodisperse spherical particles, care must be taken that
gravitational forces do not exceed interfacial forces, i.e. the Bond number does not
exceed unity, Bo = ρDPD2g/γ < 1. For our system, this means that particles must remain
below about 800µm in the wet state, or 400µm when fully dry. On the small end,
particles can be made as small as D/D0 ≈ 2, but only if high shear stresses are employed,
which can be achieved through high μCP, high QCP, or small H. Thus the minimum size
of particles is set by D0, which we found to be at minimum D0 = 15µm for our 300µm
thick membranes, resulting in 30µm wet or 15µm dry particles. However, as reported by
Yanagishita et al.31, advanced manufacturing techniques can be used to produce
membranes and particles down to D ≈ D0 ≈ 100nm.
When manufacturing particles via XME, care must be taken such that the particles
remain uniform until they are ready to be used. Unfortunately, natural processes such as
coalescence and shear break up act to widen the particle size distribution. In simple
systems such as the decanol-water system studied here, droplets readily coalesce due to
the absence of surfactant.

Addition of a surfactant does stabilize the particle size

distribution from growing larger, but also decreases the interfacial tension, and thus
weakens the droplets against shear breakup. In the PLG system studied here, droplets are
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stabilized by the surfactant PVA, and the interfacial tension continues to decrease over a
droplet's lifetime as additional surfactant is adsorbed to the interface. Our goal is to
prevent shear breakup of the nascent PLG particles until such point that the solvent is
extracted, thus generating solid particles with a stable size distribution.

Figure 5.13 – Droplet deformation Df, (squares) and droplet size
D/D0 (circles) as a function of Cadrop for the PLG system. The
deformation data utilize a linear fit, while the size data are fit according
to Eq. (5.5). Rupture occurs at Df,c = 0.4. The figure uses the same data
set presented in Figure 5.10.

Because shear is used to generate the initial monodisperse emulsions, the
operating conditions during XME are inherently close to the critical condition where
breakup of droplets occurs. For insight into this potential problem, we look to the results
of Bentley and Leal32 who used a four-roll mill to experimentally measure the
deformation and point of breakup as a function of droplet capillary number, Cadrop,
viscosity ratio, λ, and a flow parameter, α, which characterized the relative importance of
elongation and shear in the flow field. In their work, which primarily studied pure fluids,
they utilized a deformation parameter Df to measure droplet deformation, where Df = (LB)/(L+B), and L and B are the lengths of the droplet's major and minor semiaxes,
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respectively. It was shown that for λ > 1, Df will increase linearly with Cadrop until it
reaches Df,c ≈ 0.4, at which point the droplet will rupture.
The critical value of Cadrop where Df = 0.4 depends on λ and α, but typically
varied from 0.1 < Cadrop < 0.5 for λ > 1. Using the relationship between the different
capillary numbers, Cadrop = 0.5CaD/D0, we plot Df and D/D0 against Cadrop using the same
PLG data set that was previously presented. Then we calculate the ratio of Ca needed to
generate a droplet of a given size to the critical value where rupture is expected to occur,
Cac. Figure 5.13 and Figure 5.14 show these results.

Figure 5.14 – Ratio of Ca to the critical value Cac where droplet
rupture occurs, calculated as a function of the diameter ratio D/D0
and viscosity ratio λ. The solid line represents λ = 5, the dotted line is
λ = 10, and the dashed line is λ = 20.

We know already that XME can be used to generate emulsions down to D/D0 ≈ 2,
but from these calculations we learn that the process is near an unstable operating point,
where a small increase in shear rate downstream of the membrane pore could result in Ca
> Cac. As can be seen, increasing λ increases the stability of the system against shear
breakup. Fortunately, in a laminar flow, after a droplet is generated it will tend toward a
position away from the wall29, where the shear rate is lower. But care must be taken in
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constructing the areas downstream of the membrane pore, as any bends or obstructions
will increase the local shear rate, again increasing the likelihood of breakup. This
potential problem can be avoided through intelligent apparatus design, by expanding
channel dimensions downstream of the pore, thus decreasing velocities and shear rates
and thereby increasing the likelihood that the final size distribution will be uniform.

5.5 Summary
We have shown that XME is a robust technique that can be used for the
production of complex polymeric particles as well as simple emulsion droplets. The
relationship between the size of droplets and the CP shear rate, derived elsewhere from
first principles, was shown to apply equally well to the simple decanol-water system and
a complex system containing a dissolved polymer, drug, and surfactant. In contrast, the
polymer system showed an unexpected scaling of droplet size as a function of the DP
flow rate, which we have shown to be consistent with the presence of dynamic interfacial
tension. The inferred interfacial tension at a given dripping period was significantly
lower than values measured independently at the same period using the drop weight
method, which is not too surprising in light of the stagnant nature of the outer fluid in the
latter method, slowing surfactant transport to the interface. The CP velocity profile and
the thinning dynamics of the DP droplet neck were both directly observed, and both were
consistent with theoretical predictions for Newtonian fluids, indicating shear-thinning
viscosity and fluid elasticity are negligible. Detached droplets were seen to have an
ellipsoidal deformation, which increased linearly with the capillary number. Finally, the
distribution of wet droplet sizes was consistent with measurements from close-packed
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arrays of dry particles, and both result in a relative standard deviation of between 1 and
2%. In conclusion, over a wide range of conditions, the XME process can be used to
manufacture monodisperse droplets of predictable size, even when the fluids contain
dissolved polymers and surfactants.
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Chapter 6: Future Work
In the end, the desired outcome of this project was to demonstrate that cross-flow
membrane emulsification (XME) can be used for the production of drug-loaded polymer
microspheres with controllable release profiles that exceed the performance of existing
commercial products. While the original goal has not been met, the tools to accomplish
this are in place such that a researcher need only follow the recipe presented in this
chapter to make the proposed demonstration. This chapter is organized as follows. First,
we lay out the requirements for designing long-acting release (LAR) formulations in
general, and specifically a one month depot formulation of haloperidol, our model drug
of choice.

Then we review existing literature on immediate and LAR haloperidol

formulations. This is followed by a review of the parameters that can be tuned in order to
achieve the desired release duration and rate. Finally, we end with what experiments
would need to be run in order to complete the formulation design.

6.1 Formulation Requirements
The basic requirements for LAR formulations are that they are sterile, physically
and chemically stable for at least two years when refrigerated, and stable for at least one
week at room temperature. Additionally, the product should be formulated so that no
greater than 3 mL per injection site need be administered, and the product should be
easily syringable (can be pushed through a syringe without requiring excessive force)
through a 20 gauge 1.5 inch needle. Additional requirements that would improve upon
existing formulations are that an LAR product should not exhibit any burst release, and

115

should produce a near-constant release rate that is approximately equal to the average
elimination rate for the drug.
The model drug studied here, haloperidol, is especially well suited for controlled
release applications. The drug is indicated for use in the treatment of schizophrenia, as
well as the control of tics associated with Tourette's Disorder.

It is well suited for

controlled release applications1 due to the low daily dose, the drug hydrophobicity, high
non-compliance rates in the intended treatement group, and existence of doseproportional side effects2. Furthermore, the wealth of literature available on the drug aids
in the formulation design. Haloperidol is typically supplied as an oral dosage form, taken
one or two times per day3. For acute use, haloperidol injection USP is prescribed, and for
chronic use, a LAR formulation of haloperidol decanoate is prescribed for monthly
administration3. In this case study, we will attempt to design a formulation that exceeds
the performance of the existing haloperidol decanoate product.
For a theoretical haloperidol LAR formulation, a review of existing data is helpful
in the design. An assortment of physical and chemical property data are provided in
Chapter 3, and the reader is directed there for further information. Table 6.1 displays
pharmacokinetic data for intravenous and oral haloperidol, and intramuscular haloperidol
decanoate.
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Table 6.1 – Pharmacokinetic parameters for haloperidol.3-5

Parameter
Elimination half life (hr)
Volume of distribution (L/kg)
Clearance (mL/kg/min)
Elimination constant (1/hr)
Bioavailability (relative AUC0-∞b)
Plasma concentration for 10 mg oral dose (ng/mL)
Plasma concentration for 100 mg decanoate dose (ng/mL)
Plasma concentration before next dose (ng/mL)
Dosing rate for 70 kg man (mg/day)
a

Mean
26.2
21.7
10.8
0.030
0.65
7.79
7.95
2.62
2.8

SEMa
8.0
6.9
2.6
0.14
4.79
4.94
0.27
-

SEM = standard error of the mean, bAUC0-∞ = area under the concentration – time curve

A number of parameters from this table are relevant. First, the drug has an incredibly
large volume of distribution, indicating that it is absorbed in both the blood stream and
tissues throughout the body. The drug has a fairly high bioavailability, and thus the
average daily dose administered via parenteral administration should not vary
significantly from the daily oral dose. Specifically, it has been found that patients
receiving 10 mg/day oral haloperidol achieve the same steady state average blood serum
concentration when 100 mg/month haloperidol decanoate injection is utilized. We can
also calculate the desired dosing rate (i.e. the amount of haloperidol released per day) by
multiplying the clearance by the desired plasma concentration, yielding about 3 mg/day.
Thus, this is the target quantity to be released from our PLG microspheres.
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Figure 6.1 - Plot of average haloperidol blood serum concentration
following a loading dose regimen of 100 mg haloperidol equivalent
(administered as haloperidol decanoate). The dosing schedule was
once weekly for the first four weeks, then once every two weeks until
week eight, and once every four weeks after week eight.5

To achieve a release rate of 3 mg/day over the course of 30 days, then 90 mg must
be administered. A typical formulation might start with 20% drug loading (i.e. 1:4 drug
to polymer ratio in the solvent). If it is assumed that the encapsulation efficiency during
the emulsification process is 100% then a 20% drug loading of the microspheres results.
Thus, 450 mg of microspheres would be administered. To suspend the microspheres, we
assume that 100 mg microspheres per 1 mL of suspending medium would be used, and
thus our injection volume would be 4.5 mL of medium plus about 0.5 mL for the
microspheres, yielding 5 mL. Thus two separate injections would be required, in order to
stay under the 3 mL per injection site guideline. This works out to be very similar to the
marketed naltrexone LAR formulation, which has 112 mg microspheres per 1 mL of
diluent, and is administered as two separate injections.6
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6.2 Previous studies of haloperidol LAR formulations
Many other researchers have published data on LAR formulations of haloperidol.
Wang et al.7 used melt extrusion to generate haloperidol loaded rods at 40% drug loading
in a matrix of 50:50 poly(DL-lactide-co-glycolide) (PLG) (inherent viscosity 0.47 dL/g),
and compared this formulation to a 20% drug loaded solvent cast pellet.8 Although in
vitro release experiments showed a roughly 7 day lag phase before significant drug was
released from the rods, the same rods demonstrated in vivo in rats a serum concentration
maximum on day 7, and continued release into the serum up until about day 40. The
study demonstrated that melt extrusion could be used to rapidly make implants that
provide fairly consistent release over a prolonged period.
Other studies investigating incorporation of haloperidol into PLG microspheres
were conducted by Cheng et al.9 and by Budhian et al.10-11 Cheng et al. used high shear
homogenization to generate particles, while Budhian et al. used ultrasonics, and both
used a batch production system. All found relatively constant release rates in vitro, and
both studies demonstrated very low encapsulation efficiency and final drug loading,
which is not surprising given that the particles produced were between 0.1 and 10 µm.
Finally, Budhian et al. reported that the diffusivity of haloperidol in 50:50 PLG particles
8 x 10-18 cm2/s, a finding that is useful for prediction of drug release rates from particles
of different sizes.

6.3 Future XME and in vitro release experiments
The next step in the product design is the generation of microspheres that release
at a rate of 3 mg/day at a drug loading of 20%. Finding guidance from the work of other
researchers, it appears that 50:50 PLG copolymers of intermediate inherent viscosity are
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appropriate for developing once monthly LAR formulations of haloperidol. Because
PLG polymers break down by cleavage of the ester bond between lactide and/or
glycolide residues, a higher inherent viscosity (which equates to higher initial molecular
weight) results in a longer time period before the polymer completely breaks down and
the microsphere disintegrates. Thus polymer inherent viscosity is a key parameter that
can be adjusted to affect drug release rate and duration, in addition to microsphere size.
Based on this and other data reported thus far, a starting formulation for XME would look
like that presented in Table 6.2.
Table 6.2 – Starting compositions for once monthly haloperidol LAR formulation.

Continuous Phase
Component
poly(vinyl alcohol)

Composition
(%)
1

haloperidol
trace*
water
99
*
concentration needed to achieve saturation

Dispersed Phase
Component
50:50 PLG
(I.V. 0.47 dL/g)
haloperidol
dichloromethane

Composition
(%)
9.6
2.4
88

At this point, the rate of drug release for a microsphere of a given size and
composition would need to be determined. The best way to accomplish this is to run a
single XME experiment, and use the continuous phase (CP) flow rate to change
microsphere size, while holding all other process variables constant. It is recommended
that about 4 different monodisperse size samples be collected, each containing at least
200 mg of microspheres. Because the CP is saturated with the drug, no mass transfer
should occur during emulsification, and thus all samples should exhibit approximately
100% encapsulation efficiency. Using the procedures outlined in Chapter 3, the particles
should be hardened, washed, filtered and dried.
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Subsequent to the generation of the particles, the in vitro drug release can be
measured using the existing apparatus described in Chapter 3.

Briefly, the dry

microspheres are added to a dialysis chamber along with a small amount of release
medium, and this chamber is sealed and placed in a larger reservoir of medium. The
release medium recommended is phosphate buffered saline at pH of 7.4 and a
temperature of 37°C. To better simulate the release environment in vivo, a surfactant
such as polysorbate 80 should be added to the medium.

The surfactant improves

microsphere wetting, and because of the very low solubility of haloperidol in water at pH
= 7.4, it also acts to better simulate the sink conditions of the body. In addition, an agent
such as sodium azide should be employed in the release medium to control microbial
growth. The concentration of haloperidol in solution can be monitored using the inline
UV spectrometer, and if the concentration exceeds approximately 10% of the equilibrium
concentration (which is dependent on the surfactant), the release medium should be
replaced. Drug release should be monitored until no changes are observed for at least
two weeks, at which point the dialysis chamber should be removed and inspected for
particle residue. If no residue is found, then the experiment is concluded, and the release
rate, duration and total amount of drug released can be calculated.

6.4 Achieving the optimal release profile
Once a representative set of release experiments have been conducted, the
protocol of Berchane et al. can be used to calculate what combination of monodisperse
sizes should be combined to provide the closest match to the desired release profile.12
This is possible because the release rate from a mixture of monodisperse sizes is simply
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the weighted average of the individual release rates. In brief, their protocol calls for the
user to begin with a cumulative solution to the diffusion equation,
Mt
6
= 1− 2
M∞
π

∞

1

∑j
j =1

2

2

e− j π

2

T / R2

(6.1)

where Mt / M∞ is the ratio of mass released at time t to mass released at infinite time, R is
t

the radius of the microsphere, and T = ∫ D (t )dt , where D(t) is the drug diffusivity at time
0

t, which is a function of polymer molecular weight, and thus is a function of time. The

boundary and initial conditions used are c(r = R, t > 0) = 0 and c(r, t = 0) = ci, where c is
concentration and r is radial position. The diffusivity is linked to the polymer molecular
weight through an empirical polynomial relationship, and molecular weight Mw decreases
as a function of time, M w = M w (t = 0) exp(− k deg t ) , where kdeg is the degradation rate

constant. In the fitting, it is assumed that there exists an initial diffusivity, D0, which
explains the burst release, and this diffusivity is used until the calculated diffusivity D(t)
exceeds D0. The parameters D0 and kdeg are the only parameters used to fit the release
profile. This method has been demonstrated successfully in fitting release profiles for the
drug piroxicam loaded into two different grades of PLG with three different microsphere
diameters.
Modeling provides great validation that drug release can be explained by a
combination of diffusion and degradation, but ultimately we want to use the model to
predict the combination of particle sizes that will result in the desired release rate.
Berchane et al. were limited to three different size fractions, set by the standard sieve
sizes used to separate their initially polydisperse size distributions.12 Still, they used a
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non-linear least squares regression to minimize the squared error between the target
release profile and a linear combination of the available profiles, and they achieved great
success. Using XME, a much wider range of release profiles is possible, because a much
wider range of particle sizes is possible.

Instead of a discrete combination of

monodisperse size distributions, the model can be used to create a smoothly varying
function relating microsphere size and drug release rate from the initial release profiles.
Modeling could then be used to generate a more detailed particle size population for use
in constructing the ideal release profile, and a follow up XME experiment could be
performed where the exact distribution is made within a single experiment.
With the methods in this chapter as a guide, we conclude that generation of an
ideal once-monthly formulation of haloperidol-loaded PLG microspheres using crossflow membrane emulsification is readily achievable. And after this goal is achieved, the
methods can be expanded to a much wider class of drugs and release profiles, with the
potential result being a significant improvement in human health.
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